Molecular Class	Number of Molecules Altered Within Each Pathway

Nitrite (80 mg/day)

Glycerophospholipids	13

Sphingolipids	2

Glycerolipids	1

Fatty Acyls	3

Carbohydrates and Carbohydrate Conjugates	1

Carboxylic Acids and Derivatives	2

Imidazole Ribonucleosides and Ribonucleotides	1

Pyridines and Derivatives	1

Peptide Hormones	1

Unknown	20

Nitrite (160 mg/day)

Glycerophospholipids	9

Sphingolipids	2

Carboxylic Acids and Derivatives	2

Polypeptide	1

Pyridines and Derivatives	1

Unknown	18

Molecular Class	Number of Molecules Altered Within Each Pathway

Nitrite (80 mg/day)

Glycerophospholipids	13

Sphingolipids	2

Glycerolipids	1

Fatty Acyls	3

Carbohydrates and Carbohydr	1

Molecular Class	Number of Molecules Altered Within Each Pathway

ate Conjugates

Carboxylic Acids and Derivatives	2

Imidazole Ribonucleosides and Ribonucleotides	1

Pyridines and Derivatives	1

Peptide Hormones	1

Unknown	20

Nitrite (160 mg/day)

Glycerophospholipids	9

Sphingolipids	2

Carboxylic Acids and Derivatives	2

Polypeptide	1

Pyridines and Derivatives	1

Unknown	18


 	 	Total number of hits	Standard articles retrieved

Keyword search (basic topic + sex differences search)	Stroke	301	33/94

 (stroke AND sex difference*); filters: human, Englishor(diabetes AND sex difference*); filters: human, English	Diabetes	539	23/95

TTUHSC SGSH PubMed search tool: Basic	Stroke	566	50/94

 (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR gender based) AND (gender[ti] OR sex[ti]); filters: human, EnglishTotal number of hits at the time of validation: 21,315	Diabetes	1027	62/95

TTUHSC SGSH PubMed search tool: Expanded	Stroke	1623	77/94

 (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR female) AND (gender[ti] OR sex[ti] OR women[ti] OR female[ti]); filters: human, EnglishTotal number of hits at the time of validation: 97,972	Diabetes	5569	81/95

		Total number of hits

Keyword search (basic topic + sex differences search)	Stroke	301

(stroke AND sex difference*); filters: human, Englishor(diabetes AND sex difference*); filters: human, English	Diabetes	539

TTUHSC SGSH PubMed search tool: Basic	Stroke	566

(sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR gender based) AND (gender[ti] OR sex[ti]); filters: human, EnglishTotal number of hits at the time of validation: 21,315	Diabetes	1027

TTUHSC SGSH PubMed search tool: Expanded	Stroke	1623

(sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR female) AND (gender[ti] OR sex[ti] OR women[ti] OR female[ti]); filters: human, EnglishTotal number of hits at the time of validation: 97,972	Diabetes	5569


Age (M, SD)

Gender (males:females)

CARS (M, SD)


Dietary change	Epigenetic effects	Outcome	Species	Reference

Vitamin B12, folate and methionine deficient	DNA methylation	Hypomethylation in methyl-deficient diet	Sheep	Sinclair et al., 2007

Betaine supplementation	DNA methylation	Increased global measures of DNA methylation	Chicks	Hu et al., 2015

Betaine supplementation	DNA methylation, Histone modification	PEPCK1 hypomethylated and enriched for H3K27me3. PEPCK2 and FBP1 hypermethylated and enriched for H3K4me3	Neonatal Piglets	Cai et al., 2014

Zinc supplementation	DNA methylation	Hypomethylation and increased expression of gene A20	Hens	Li et al., 2015

Variable zinc levels	DNA methylation	Hypermethylation in regulatory regions of gene ZIP4	Piglets	Karweina et al., 2015

Restrictive feeding	Histone modification	Increased global measures of H3K9 acetylation and reduction in H3K9me3 in IUGR pigs subjected to restrictive feeding	Pigs	Nebendahl et al., 2016

Folic acid supplementation	DNA methylation	Hypermethylation in IUGR piglets with folic acid supplementation compared to piglets fed control diet	Pigs	Jing-bo et al., 2013

Maternal protein insufficiency	DNA methylation	Hypomethylation in POMC and GR in the sheep brain	Sheep	Begum et al., 2012

Methylating micronutrients	DNA methylation	IYD gene differentially methylated between groups of pigs with extreme obesity related phenotypes	Pigs	Braunschweig et al., 2012

Dietary change	Epigenetic effects	Outcome	Species	Reference

Vitamin B12, folate and methionine deficient	DNA methylation	Hypomethylation in methyl-deficient diet	Sheep	Sinclair et al., 2007

Betaine supplementation	DNA methylation	Increased global measures of DNA methylation	Chicks	Hu et al., 2015

Betaine supplementation	DNA methylation, Histone modification	PEPCK1 hypomethylated and enriched for H3K27me3. PEPCK2 and FBP1 hypermethylated and enriched for H3K4me3	Neonatal Piglets	Cai et al., 2014

Zinc supplementation	DNA methylation	Hypomethylation and increased expression of gene A20	Hens	Li et al., 2015

Variable zin	DNA meth	Hype	Piglets	Ka

c levels	ylation	rmethylation in regulatory regions of gene ZIP4		rweina et al., 2015

Restrictive feeding	Histone modification	Increased global measures of H3K9 acetylation and reduction in H3K9me3 in IUGR pigs subjected to restrictive feeding	Pigs	Nebendahl et al., 2016

Folic acid supplementation	DNA methylation	Hypermethylation in IUGR piglets with folic acid supplementation compared to piglets fed control diet	Pigs	Jing-bo et al., 2013

Maternal protein insufficiency	DNA methylation	Hypomethylation in POMC and GR in the sheep brain	Sheep	Begum et al., 2012

Methylating micronutrients	DNA methylation	IYD gene differentially methylated between groups of pigs with extreme obesity related phenotypes	Pigs	Braunschweig et al., 2012


M	Two-point LOD score values at recombination fraction (θ=)	Zm	θmax

0.0	0				0


	Histological results

HPV Genot	< CI	CIN 2(n = 	CIN 3(n	IC


Region	Methylation status	# CpG in	# of molecules detected	% of total

MseI frag.	Ampl-icon	Exp 1	Exp 2	Exp 3	Exp 4

1	unmethylated	0	0	1	0			3.0

Hha-methylated	2	0	0	0

HpaII-methylated	11	2	1	0			3.0

Fully methylated	54	11	15	16			93.9

2	unmethylated	0	0	1	1			11.8

Hha-methylated	0	0	0	0

HpaII-methylated	2	1	1	0			5.9

Fully methylated	12	11	6	8			82.4

3	unmethylated	0	0	15	14	7	5	80.4

Hha-methylated	3	2	0	0	0	0	0

HpaII-methylated	3	1	0	0	0	0	0

Fully methylated	23	17	0	6	1	3	19.6

Region	Methylation status	# CpG in	# of molecules detected

MseI frag.	Ampl-icon	Exp 1	Exp 2	Exp 3	Exp 4

1	unmethylated	0	0	1	0

Hha-methylated	2	0	0	0

HpaII-methylated	11	2	1	0

Fully methylated	54	11	15	16

2	unmethylated	0	0	1	1

Hha-methylated	0	0	0	0

HpaII-methylated	2	1	1	0

Fully methylated	12	11	6	8

3	unmethylated	0	0	15	14	7	5

Hha-methylated	3	2	0	0	0	0

HpaII-methylated	3	1	0	0	0	0

Fully methylated	23	17	0	6	1	3


			Trial I (unselective supplementation in all mothers from week 18)		Trial II (selective supplementation in nutritionally at risk mothers from week 28)

Trial Group			Protein, Carbohydrate and Vitamins1	Carbohydrate and vitamins2	Vitamins only3	p7	Protein, Carbohydrate and Vitamins4	Carbohydrate and vitamins5	Vitamins only6	p7

	Mean Birthweight kg	Original trial (n)	3.01 ± 0.06 (47)	3.02 ± 0.07 (50)	3.06 ± 0.07 (45)	0.87	3.34 ± 0.14 (14)	2.95 ± 0.15 (17)	3.01 ± 0.07 (14)	0.09

		Traced participants (n) 	2.97 ± 0.07 (40)	2.96 ± 0.07 (41)	3.07 ± 0.08 (38)	0.53	3.34 ± 0.14 (14)	2.96 ± 0.17 (15)	3.01 ± 0.07 (13)	0.15

		Assessed in clinic (n)8	3.11 ± 0.09 (21)	2.95 ± 0.08 (23)	3.08 ± 0.12 (21)	0.48	3.23 ± 0.13 (8)	3.42 ± 0.15 (4)	3.03 ± 0.11 (8)	0.18

	Trial I (unselective supplementation in all mothers from week 18)		Trial II (selective supplementation in nutritionally at risk mothers from week 28)

	Protein, Carbohydrate and Vitamins1	Carbohydrate and vitamins2	Vitamins only3	p7	Protein, Carbohydrate and Vitamins4	Carbohydrate and vitamins5	Vitamins only6	p7

Assessed in clinic (n)8	3.11 ± 0.09 (21)	2.95 ± 0.08 (23)	3.08 ± 0.12 (21)	0.48	3.23 ± 0.13 (8)	3.42 ± 0.15 (4)	3.03 ± 0.11 (8)	0.18


Independent variables1	Coefficients (SE)	z-value(P value)	Odds ratio (OR)	95% CI OR

Age	−0.005 (0.01)	−0.49 (0.63)	0.99	(0.98, 1.01)


Factors	Domains	Major themes and their dimensions

Enabling	Availability of support	Formal support

		 Conflict with centre's hours of operation

		 Lack of an effective appointment reminder system

		 Proximity to the centre

		 Difficulties in locating the centre

		 Regular physician visits

		Informal support

		 Dependent on family assistance

		 Family responsibilities

	Familiarity with resources	Diabetes education centre and its services

		 Familiarity with DEC services

Predisposing	Self-efficacy	Diabetes self-management

		 Sufficient amount of information

		 Adherent to self-management activities

		 Non-adherent to self-management activities

	Attitudes	Diabetes education

		 Level of priority

		 Apathy

	Co-morbidity	Competing health conditions

Need	Perceived/evaluated	Disease severity

		 Patient judgment of severity

		 Physician judgment of severity

Factors	Domains	Major themes and their dimensions

		of severity

		Physician judgment of severity


Outcome	RR	95% Confidence interval	p-value

Total cesarean SSIs	1.10	0.58–2.08	0.765

Cesarean incisional SSIs	0.23	0.03–1.78	0.158

Cesarean organ/space SSIs	1.62	0.83–3.18	0.160

utcome		terval	e

Total cesarean SSIs	1.10	0.58–2.08	0.765

Cesarean incisional SSIs	0.23	0.03–1.78	0.158

Cesarean organ/space SSIs	1.62	0.83–3.18	0.160


Variable	b	SE	Wald	p	Odds ratio (95% CI)

Unadjusted model

EAL	0.25	.20	1.59	.207	1.28 (0.87, 1.89)

C	−	.01	1,42		0.82


Year	Milestone	References

1994	Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis	[4]

1997	Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319	[3]

1998	Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75	[13]

1999	Discovery of LEDGFp75 using autoantibodies from a cataract patient	[14]

2000	Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients	[3]

2001–2002	Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies	[32, 98]

2003–2004	Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration	[17-20]

2004	Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals	[125]

2004	Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75	[62]

2005	Identification of DFS70/LEDGFp75 as a tumor associated autoantigen	[99]

2005	Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions	[7]

2008	Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD	[28]

2011–2012	Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD	[26, 107]

2012	Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies	[5]

2012	Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies	[6]

2013	First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/ LEDGFp75 antibodies	N/A

Year	Milestone

1994	Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis

1997	Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319

1998	Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75

1999	Discovery of LEDGFp75 using autoantibodies from a cataract patient

2000	Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients

2001–2002	Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies

2003–2004	Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration

2004	Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals

2004	Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75

2005	Identification of DFS70/LEDGFp75 as a tumor associated autoantigen

2005	Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions

2008	Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD

2011–2012	Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD

2012	Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies

2012	Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies

2013	First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/ LEDGFp75 antibodies


	Group I (n=29)	Group II (n=31)	Group III (n=24)	Group IV (n=32)	Group V (n=27)	P values *

	Severe inflammation in semen	Severe inflammation in EPS and/or post-M	Mild inflammation in semen, EPS and/or post-M	Oligospermia without inflammation	Controls

Age (y)	33.6 ± 6.2	31.0 ± 7.8	31.7 ± 5.2	32.2 ± 6.6	30.0 ± 5.2	NS


Characteristicb	Cases	Controls

	Adult Glioma Study (n = 622)	The Cancer Genome Atlas (n = 70)	Adult Glioma Study (n = 602)	Illumina iControls (n = 3,390)

Age	55 ± 0.5	54 ± 1.7	56 ± 0.6	29 ± 0.4

GENDER

Male	398 (64%)	40 (57%)	319 (53%)	1,254 (37%)

Female	224 (36%)	30 (43%)	283 (47%)	2,136 (63%)

TUMOR SUBTYPE

Grade III	97 (16%)	0 (0%)	–	–

Grade IV	525 (84%)	70 (100%)	–	–

Characteristicb	Cases

	Adult Glioma Study (n = 622)

Age	55 ± 0.5

GENDER

Male	398 (64%)

Female	224 (36%)

TUMOR SUBTYPE

Grade III	97 (16%)

Grade IV	525 (84%)


	Components	East-West	North-South	Vertical

RMS

Relative positioning	Code (m)	0.66	1.07	1.80

Carrier-phase (cm)	1.35	2.49	3.15

Velocity estimation (cm/s)	1.35	1.70	3.23


	Estimate	Standard error

Reference value: the fifth graders

Intercept	-0.89	0.13

Strategy	-0.37	0.09

Cued strategy	1.18	0.09

Correct sum	0.00	0.00

Sum of unit digits	0.02	0.02

Arithmetic fluency	-0.01	0.01

Age value: the third graders

Age	0.11	0.19

Age × Strategy	1.03	0.12

Age × Cued strategy	-0.82	0.12

Age × Sum of unit digits	0.00	0.04

Age × Correct sum	0.00	0.00

Age × Arithmetic fluency	0.01	0.01

Age value: the seventh graders

Age	-0.42	0.18

Age × Strategy	0.09	0.13

Age × Cued strategy	1.27	0.13

Age × Correct sum	0.00	0.00

Age × Sum of unit digits	-0.03	0.04

Age × Arithmetic fluency	0.01	0.01


Disease category	# of specific genes	Total genes	% of specific genes

ASD	189	321	69.8

FASD	27	106	25.5

CP	23	124	22.1


Metabolite	Gene involved in biosynthesis	Locus number	Biological Evidence	Reference

Pyoverdine	pvdSL; pvdIJKDEONMP; fpvI; pvdA	PSF113_1749-1750; PSF113_1836-1847; PSF113_1856-1860	Yes	[2]

Pyridine-2,6-bis-thiocarboxylic acid (PDTC)	pdtCKPELMFGHIJON	PSF113_2605-2618	No

2,4 diacetyl-phloroglucinol (DAPG)	phlIEDBCAFGH	PSF113_2457-2464	Yes	[4]

Hydrogen cyanide (HCN)	hcnABC	PSF113_2367-2369	Yes	[83]

Putative Lankacidin	lkcABCDEFGJ; pqqFABCDEG	PSF113_3657-3666; PSF113_5383-5388	No

PKS-like metabolite	 	PSF113_3045-3053	No


Parameter	P	Odds ratio (OR)	95% confidence interval (CI)

Maternal age	0.846	0.995	0.943–1.050

Multiparity	0.293	0.751	0.459–1.235

Previous uterine surgery (including myomectomy, caesarean section, reconstructive surgery, or septum resection)	0.490	1.132	0.718–1.784

BMI

 Extremely low (under 18.5) 	0.402	0.538	0.126–2.290

 High (above 30)	0.544	0.764	0.320–1.823

Supernumerary embryos developed in IVF cycle	0.275	1.269	0.827–1.946

Transfer of 2 embryos	0.043	1.952	0.020–3.735

Spontaneous cycle ET	0.064	0.417	0.150–1.164


	Abrupt	Gradual 1	Gradual 2	All treatments

Randomized, n	41	40	42	123

Safety population, n	40	39	42	121

Completed, %	75	72	88	79

Discontinued, %	25	28	12	21

 Adverse event	5	15	5	8

 Withdrew consent	10	8	0	6

 Insufficient response	5	0	0	2

 Lost to follow-up	0	3	2	2

 Noncompliance	0	0	2	1

 Other	5	3	2	2

	Abrupt

Randomized, n	41

Safety population, n	40

Completed, %	75

Discontinued, %	25

Adverse event	5

Withdrew consent	10

Insufficient response	5

Lost to follow-up	0

Noncompliance	0

Other	5


Cat Demographics	Free Cats n = 73 (%)	Normal-Fee Cats n = 78 (%)

Cat Ages

Age range	1–16 years	1–14 years

Age mean	4 years	3 years

Cat Sex

TOTAL females	52 (71)	57 (73)

Female adults	46 (63)	54 (69)

Female matures	6 (8)	3 (4)

TOTAL males	21 (29)	21 (27)

Male adults	16 (22)	19 (24)

Male matures	5 (7)	2 (3)

Pelage Varieties

Blacks and Browns	9 (12)	6 (8)

Calicos and Tortoiseshells	8 (11)	17 (22)

Brindles and Gingers	9 (12)	4 (5)

Greys and Whites	9 (12)	13 (17)

Piebalds	12 (16)	13 (17)

Tabbies	26 (36)	25 (32)

Cat Fate

Alive and Retained by original adopter	68 (93)	75 (96)

1 Dead	3 (4)	0 (0)

2 Returned to shelter	0 (0)	3 (4)

3 Rehomed privately	1 (1)	0 (0)

4 Ran away	1 (1)	0 (0)

Cat Demographics	Free Cats n = 73 (%)	Normal-Fee Cats n = 78 (%)

Cat Ages

Age range	1–16 years	1–14 years

Age mean	4 years	3 years

Cat Sex

TOTAL females	52 (71)	57 (73)

Female adults	46 (63)	54 (69)

Female ma	6 (8)	3 (4

Cat Demographics	Free Cats n = 73 (%)	Normal-Fee Cats n = 78 (%)

tures		)

TOTAL males	21 (29)	21 (27)

Male adults	16 (22)	19 (24)

Male matures	5 (7)	2 (3)

Pelage Varieties

Blacks and Browns	9 (12)	6 (8)

Calicos and Tortoiseshells	8 (11)	17 (22)

Brindles and Gingers	9 (12)	4 (5)

Greys and Whites	9 (12)	13 (17)

Piebalds	12 (16)	13 (17)

Tabbies	26 (36)	25 (32)

Cat Fate

Alive and Retained by original adopter	68 (93)	75 (96)

1 Dead	3 (4)	0 (0)

2 Returned to shelter	0 (0)	3 (4)

3 Rehomed privately	1 (1)	0 (0)

4 Ran away	1 (1)	0 (0)


 	Bariatric Surgery (N = 34)	Lifestyle Intervention (N = 34)	P

Age (yrs)	43.3 ± 9.4	40.9 ± 10.5	0.33

% Female	76.5	76.5	1.00

% Race	 	 	0.25

 White	79.4	70.6

 African-American	5.9	14.7

 American Indian/Alaskan Native	2.9	0.0

 Native Hawaiian/Other Pacific Islander	2.9	0.0

 Other	8.8	5.9

 Don’t know	0.0	8.8

% Ethnicity	 	 	1.00

 Non-Hispanic	91.2	91.2

 Hispanic	8.8	8.8

BMI (kg/m2)	46.2 ± 7.8	45.0 ± 4.9	0.49

Weight (kg)	129.9 ± 27.6	127.7 ± 19.6	0.71


Age

Gender

Female

Male

Acute myocardial infarction

Comorbidities

Hypertension

Diabetes mellitus

Dyslipidemia

Arrhythmia

Heart failure

Valvular heart disease

Peripheral vascular disease


Registered indications	Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with

	-Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41]

	- Acquired hemophilia [42]

	- Congenital factor VII deficiency [43]

	- Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44]

Potential indications	Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46]

	Treatment of bleedings after all conventional measures have failed in patients with

	- Chronic liver disease [47]

	- Thrombocytopathy [48]

	- Platelet-refractory thrombopenia [49]

	- Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4)

	- Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50]


Hol	Tul	Ban	Bis	Gau	Mit	Yak	Anc	BubB	BubC	Ind	Mur	Syn	Ela


Domain/outcome	Questionnaire/items	Assessment time point	Reference

Primary Outcome	 	t1	t2	t3	t4

Physical functioning	Hannover Functional Ability Questionnaire (FfbH-R)	x	x	x	x	[51]

Secondary Outcomes

Pain

 Pain intensity	Numeric Rating Scale (NRS)	x	x	x	x	[52]

 Pain status	Graded Chronic Pain Status (GCPS)	x	x	x	x	[53]

Physical activity	Freiburg questionnaire on physical activity (FFkA)	x	 	x	x	[54]

Emotional functioning

 Depression	Patient Health Questionnaire (PHQ-D)	x	x	x	x	[55]

 Anxiety	Generalized anxiety disorder 7-item scale (GAD-7)	x	x	x	x	[56]

Health related quality of life	Short-Form-12 (SF-12)	x	x	x	x	[57]

Stress	Perceived Stress Scale (PSS)	x	x	x	x	[58]

Pain related cognitions, emotions and behavior

 Cognitive and behavioral pain coping strategies	Pain Management Questionnaire (FESV)	x	x	x	x	[59]

 Fear-avoidance and endurance-related responses to pain	Avoidance-Endurance Questionnaire (AEQ)	x	x	x	x	[60]

 Pain related fear	Tampa Scale for Kinesiophobia (TSK)	x	x	x	x	[61,62]

Motivational and volitional determinants of physical activity

 	risk perception (3 items), self-efficacy (3 items), outcome expectancies (11items), experiences with physical activity (5 items), self-concordance (12 items), intention (7 items), action (4 items) and coping (4 items) planning, action control (6 items)	x	x	x	x	[63-67]

 Stage of change algorithm for physical activity	two Items (Have you performed moderate physical for 30 minutes or longer on a minimum of 3 days per week? and "Since when are you as regularly active as you are now?"; possible answers: 1. Question: no, and I don’t intend to do so; no, but I am thinking about doing so; no, but I have the strong intention to do so; yes, but it is difficult to me; yes, and it is easy for me; 2. Question: open)	x	x	x	x	[68,69]

Attitudes towards performing physical activity	modified Version of Short-Questionnaire to measure cognitive and affective attitudes toward sports activities	x	x	x	x	[70]

Treatment satisfactions with exercise therapy	18 items (e.g. “I would recommend the exercise therapy other patients.” measured by using a six-point ordinal scale with 1= “absolutely agree”, 6=“absolutely disagree”; e.g. “The time extent of the exercise therapy, I perceived as...” measured by using a five-point ordinal scale with 1=“far too high“, 5=“far too low“; e.g. “Overall, how do you rate the exercise therapy?” measured by using a six-point ordinal scale with 1= “very satisfied”, 6=not “satisfied at all”)	 	x	 	 	self-designed

Treatment satisfactions with the rehabilitation process	five items (e.g. “Overall, how do you rate the rehabilitation process?”) measured by using a ten-point ordinal scale (1= “very poor”, 10 = „excellent“)	 	x	 	 	self-designed

Others

 Demographic characteristics	sex, age, height, nationality, marital status, education, monthly income, weight, self-reported work status	x	 	 	 	[71]

 Social medical characteristics	a) self-reported low back pain related sick leave, use of health care services, medication use for the last six month and self-reported plan to apply for retirement, severe disabilities	x	 	 	 	[71]

 	b) diagnosis, work status and physical capability taken from the hospital discharge report	 	x

 Aftercare	a) aftercare recommendations taken from the hospital discharge report	 	x	 	 	self-designed

b) self-designed; five items (e.g. “Have you participated in the last twelve months in a medically prescribed exercise therapy to rehabilitation aftercare?” with the option to answer yes/no)	 	 	 	x

Job satisfaction	scale on job satisfaction (IRES-3)	 	 	x	x	[72]


	Incremental Difference: Complete Banvs.Current Legislation	Incremental Difference: Optimistic Case	Incremental Difference: Worst Case

Gross Intervention Costs (C)	3,994,645	1,996,438	5,067,102

AMI Treatment Costs Saved (T)	40,051,602	237,927,598	1,626,740

All Tobacco-Attributable Treatment Costs Saved (T)	99,609,250	946,905,837	2,527,779

Net Costs (AMI Treatment) *(C-T)	–36,056,957	–235,931,160	3,440,362

Net Costs (All Tobacco-Attributable Disease Treatment) * (C-T)	–95,614,605	–944,909,399	2,539,322

AMI Cases Averted (A)	17,478	53,361	13,109

Smokers Quitting (Q)	221,154	385,100	46,060

Life Years Gained (L)	437,589	891,945	45,268

Incremental Cost-Effectiveness Ratios

Cost per LY Gained (C-T)/(L)	Cost Saving	Cost Saving	56 (USD) Highly Cost-Effective

Cost per LY Gained w/out Medical Treatment Saved (C/L)	9.13 (USD) Highly Cost-Effective	2.24(USD) Highly Cost-Effective	112 (USD) Highly Cost-Effective

Cost per AMI Case Averted (C-T)/A	Cost Saving	Cost Saving	262 (USD) Highly Cost-Effective

Cost per AMI Case Averted w/out Medical Treatment Saved (C/A)	229 (USD) Highly Cost-Effective	37 (USD) Highly Cost-Effective	387 (USD) Highly Cost-Effective

	Incremental Difference: Complete Banvs.Current Legislation	Incremental Difference: Optimistic Case	Incremental Difference: Worst Case

Gross Intervention Costs (C)	3,994,645	1,996,438	5,067,102

AMI Treatment Costs Saved (T)	40,051,602	237,927,598	1,626,740

A	9	946,905,8	2

ll Tobacco-Attributable Treatment Costs Saved (T)	9,609,250	37	,527,779

Net Costs (AMI Treatment) *(C-T)	–36,056,957	–235,931,160	3,440,362

Net Costs (All Tobacco-Attributable Disease Treatment) * (C-T)	–95,614,605	–944,909,399	2,539,322

AMI Cases Averted (A)	17,478	53,361	13,109

Smokers Quitting (Q)	221,154	385,100	46,060

Life Years Gained (L)	437,589	891,945	45,268

Incremental Cost-Effectiveness Ratios

Cost per LY Gained (C-T)/(L)	Cost Saving	Cost Saving	56 (USD) Highly Cost-Effective

Cost per LY Gained w/out Medical Treatment Saved (C/L)	9.13 (USD) Highly Cost-Effective	2.24(USD) Highly Cost-Effective	112 (USD) Highly Cost-Effective

Cost per AMI Case Averted (C-T)/A	Cost Saving	Cost Saving	262 (USD) Highly Cost-Effective

Cost per AMI Case Averted w/out Medical Treatment Saved (C/A)	229 (USD) Highly Cost-Effective	37 (USD) Highly Cost-Effective	387 (USD) Highly Cost-Effective


	stx1a	stx2a

ST21	353	20

SLV of ST21	5	1

ST29	1	27

SLV of ST29	0	0

Total	359	48


	T. trichiura Uganda	T. trichiura China	T. trichiura Ecuador

T. trichiura Uganda		0.979**	0.932***

T. trichiura China	0.984**		0.551*

T. trichiura Ecuador	0.967***	0.778*

	T. trichiura Uganda	T. trichiura China	T. trichiura Ecuador

T. tri		0.	0.

chiura Uganda		979**	932***

T. trichiura China	0.984**		0.551*

T. trichiura Ecuador	0.967***	0.778*


Experimental treatment	Staphylococcus aureus	Streptococcus agalactiae	Group G Streptococci	Streptococcus pyogenes	Streptococcus pneumoniae	Biofilm-forming strainS. aureus (ATCC 25923)	Nonbiofilm-forming strainE. coli (ATCC 25922)

OD ± SD	OD ± SD	OD ± SD	OD ± SD	OD ± SD	OD ± SD	OD ± SD

(+ve control)	± 0.002		116 ± 0.004	.001	 0.001	7 ± 0.004	0.116 ± 0.002

Without compound	0.257 ± 0.003	0.216 ± 0.005	0.206 ± 0.055	0.202 ± 0.099	0.214 ± 0.030	0.216 ± 0.005	0.211 ± 0.002

With BHI broth (−ve control)	0.057 ± 0.038	0.050 ± 0.006	0.021 ± 0.002	0.069 ± 0.020	0.095 ± 0.012	0.084 ± 0.006	0.084 ± 0.006

Without compound	0.254 ± 0.003	0.243 ± 0.045	0.211 ± 0.002	0.243 ± 0.045	0.270 ± 0.042	0.243 ± 0.002	0.208 ± 0.074


		Aurora A and p27 expression	P

		2H	1H1L	2L

Sex

Male	63	54	7	2	0.191

Female	17	15	2	0

Age (years)

<60	27	22	5	0	0.071

>=60	53	47	6	0

Tumor volume (cm3)

<=5	46	40	6	0	0.203

>5	34	29	3	2

Tumor location

Up	19	15	4	0	0.687

Middle	22	19	3	0

Down	39	35	4	0

Pathological grade

II	26	20	6	0	0.991

II–III	25	25	0	0

III	29	24	3	2

Invasion stage

Mucosal and submucosal	1	1	0	0	0.372

Muscular layer	8	7	1	0

Serous membrane and outmembrane	71	61	8	2

Lymph node metastasis

0	17	16	1	0	0.510

1–6	36	29	7	0

>=7	27	24	3	0

TNM stage

I	5	5	0	0	0.031

II	22	19	3	0

III	46	41	3	2

IV	7	4	3	0

Total	80				80

		Aurora A and p27 expression	P

		2H	1H1L	2L

Middle	22	19	3	0	0.687

Down	39	35	4	0

Pathological grade

II	26	20	6	0	0.991

II–III	25	25	0	0

III	29	24	3	2

Invasion stage

Mucosal and submucosal	1	1	0	0	0.372

Muscular layer	8	7	1	0

Serous membrane and outmembrane	71	61	8	2

Lymph node metastasis

0	17	16	1	0	0.510

1–6	36	29	7	0

>=7	27	24	3	0

TNM stage

I	5	5	0	0	0.031

II	22	19	3	0

III	46	41	3	2

IV	7	4	3	0

Total	80				80


Inhalation repeats	PIF cut-off value (L/min)	Sensitivity (%)	Specificity (%)	AUC	Positive predictive value (%)	Negative predictive value (%)

I	140	84	53	0.69	81	59

II	120	86	69	0.83	69	86

III	100	89	76	0.89	59	95

IV	100	87	71	0.86	48	95


Con	N	N	N	N	N	T	A	T	A	A	A	D	W	N	N	N	N	N	N	N	N


FIGO stage after definitive histology

PresumedStage on MR	I		I	IIA	II	I	Tota


Women (%)

Age (y)

BMI (kg/m2)

Waist circumference (cm)

Waist-to-hip ratio

Sum of 4 ST (mm)

Truncal fat (%)

Total body fat (%)

Body fat mass (kg)

Systolic blood pressure (mmHg)

Diastolic blood pressure (mmHg)

Glucose (mg/dL)

Insulin (μU/mL)**

HOMA-IR**

Total cholesterol (mg/dL)

HDL-c (mg/dL) †

LDL-c (mg/dL)

Triacylglycerol (mg/dL)

Total cholesterol-to-HDL-c ratio†

Uric acid (mg/dL)

GPx activity (nmol/[mL/min])‡

Selenium (ng/g of nail)§

Zinc (μg/g of nail)§

Copper (μg/g of nail)§


Observation	Genotype	Males	Females

Body weight (g)	WT	31.5 ± 18.8	20.3 ± 0.9

	TG	25.5 ± 1.7*	22.2 ± 0.9

Body length (mm)	WT	92.8 ± 0.9	86.6 ± 0.5

	TG	89.4 ± 1.0*	87.8 ± 1.1

Grip strength (score 0–4)	WT	2.4 ± 0.2	1.0 ± 0

	TG	0.8 ± 0.2**	1.6 ± 0.2

Wire maneuver (score 0–4)	WT	1.4 ± 0.2	2.8 ± 0.5

	TG	4.0 ± 0***	2.0 ± 0.6

Tail elevation (score 0–2)	WT	2.0 ± 0	1.4 ± 0.2

	TG	1.2 ± 0.2*	1.2 ± 0.2

Observation

Body weight (g)

Body length (mm)

Grip strength (score 0–4)

Wire maneuver (score 0–4)

Tail elevation (score 0–2)


	n	Age (years)	Education (years)	Frailty index	Social vulnerability index	Protection index	CASI error at baseline

Alive at second follow-up	2,759	76.9 (4.0)	10.7 (3.2)	0.14 (0.08)	0.24 (0.12)	0.37 (0.11)	14.1 (9.9)

Dead at second follow-up	1,086	80.3 (5.3)	10.0 (3.2)	0.18 (0.10)	0.29 (0.0.13)	0.32 (0.13)	27.4 (24.1)


ID	No. of seed	FA level	Oleic acid (C18:1)	Linoleic acid (C18:2)	Linolenic acid (C18:3)	Erucic acid (C22:1 )

WG4-3	18	Mean ± SD a	20.1 ± 2.4**	2.7 ± 0.9**	3.0 ± 0.8**	65.5 ± 3.4**

M	26.3	4.7	5.


Sample ID	Tumor type	Tumor cell (%)	Sequencing depth (x)	JAK2 p.V617F allele fraction (%)	Co-occurring mutation (allele fraction %)

592	Non-small cell carcinoma	30	1999	8.2	KRAS p.G12V (17.2)

664	Adenocarcinoma with squamous features	50	1996	7	BRAF p.V600E (27.3)

717	Adenocarcinoma	40	1273	2	-

915	Favoring adenocarcinoma	60	1539	2.1	EGFR exon19 del (52.1)

1182	Adenocarcinoma	40	1997	2.4	BRAF p.V600E (10.4)

1200	Mucinous adenocarcinoma	10	1422	10.5	KRAS p.G12V (4.8)

1527	Adenocarcinoma	30	1997	10.8	-

1588	Adenocarcinoma, acinar type	20	892	6.5	-

1825	Adenocarcinoma with mucinous features	30	1998	13.4	KRAS p.G12C (25.4)

Sample ID	Tumor type	Tumor cell (%)	Sequencing depth (x)	JAK2 p.V617F allele fraction (%)	Co-occurring mutation (allele fraction %)

	Non-small cel	30	1999	8.	KRAS p.

Sample ID	Tumor type	Tumor cell (%)	Sequencing depth (x)	JAK2 p.V617F allele fraction (%)	Co-occurring mutation (allele fraction %)

592	l carcinoma			2	G12V (17.2)

664	Adenocarcinoma with squamous features	50	1996	7	BRAF p.V600E (27.3)

717	Adenocarcinoma	40	1273	2	-

915	Favoring adenocarcinoma	60	1539	2.1	EGFR exon19 del (52.1)

1182	Adenocarcinoma	40	1997	2.4	BRAF p.V600E (10.4)

1200	Mucinous adenocarcinoma	10	1422	10.5	KRAS p.G12V (4.8)

1527	Adenocarcinoma	30	1997	10.8	-

1588	Adenocarcinoma, acinar type	20	892	6.5	-

1825	Adenocarcinoma with mucinous features	30	1998	13.4	KRAS p.G12C (25.4)


Ligand	Kd (μM)

α-KG	34.4 ± 6.63

NOG	5.35 ± 1.26

Succinate	ND

U	ND

T	32.0 ± 5.24

5hmU	30.5 ± 5.59

5fU	108 ± 13.0

5caU	ND


Category	Gene	Homolog	WT1	WT2	MT	Description	Reference

Iron transport	Ftr1	HMPREF1120_04509	6.76	64.20	53.35	High-affinity iron transporter	Stearman et al., 1996

	Fet3	HMPREF1120_04510		42.88	23.29	Ferrooxidoreductase Fet3

	SidF	HMPREF1120_01438	4.55	3.58	5.95	Acetyl CoA:N6-hydroxylysine acetyl transferase	Chen et al., 2014

	SidD	HMPREF1120_01440	8.74	4.41	6.92	Nonribosomal peptide synthase Pes1

	SidA	HMPREF1120_07635	7.34	4.25	8.73	L-ornithine N5-oxygenase

	SidC	HMPREF1120_07636	2.46			Nonribosomal siderophore peptide synthase SidC

	Sit1	HMPREF1120_01434	4.47	7.10		MFS transporter, SIT family, siderophore-iron: H+ symporter	Heymann et al., 2000; Petris, 2004

		HMPREF1120_02555	7.07	5.76	7.22	MFS transporter, SIT family, siderophore-iron: H+ symporter

		HMPREF1120_07838	14.26	16.02	10.33	MFS transporter, SIT family, siderophore-iron: H+ symporter

Copper pransport	Crt	HMPREF1120_00028			4.74	Copper transporter family	Petris, 2004

		HMPREF1120_05417			7.31	Copper transporter family

		HMPREF1120_00028			4.72	Copper transporter

	Atx1	HMPREF1120_03801			4.78	Heavy metal associated domain, Cu receptor	Lin et al., 1997

Category	Gene	Homolog	WT1	WT2	MT	Description	Reference

	SidF	HMPREF1120_01438	4.55	3.58	5.95	Acetyl CoA:N6-hydroxylysine acetyl transferase	Chen et al., 2014

	SidD	HMPREF1120_01440	8.74	4.41	6.92	Nonribosomal peptide synthase Pes1

	SidA	HMPREF1120_07635	7.34	4.25	8.73	L-ornithine N5-oxygenase

	SidC	HMPREF1120_07636	2.46			Nonribosomal siderophore peptide synthase SidC

	Sit1	HMPREF1120_01434	4.47	7.10		MFS transporter, SIT family, siderophore-iron: H+ symporter	Heymann et al., 2000; Petris, 2004

		HMPREF1120_02555	7.07	5.76	7.22	MFS transporter, SIT family, siderophore-iron: H+ symporter

		HMPREF1120_07838	14.26	16.02	10.33	MFS transporter, SIT family, siderophore-iron: H+ symporter

Copper pransport	Crt	HMPREF1120_00028			4.74	Copper transporter family	Petris, 2004

		HMPREF1120_05417			7.31	Copper transporter family

		HMPREF1120_00028			4.72	Copper transporter

	Atx1	HMPREF1120_03801			4.78	Heavy metal associated domain, Cu receptor	Lin et al., 1997


Structural themes	Referential themes

To be prepared for emergency situations	Focus on overview of accident site and patient and on need of feedback

To observe the situation -Ready to act Confirmation and Validation of one’s knowledge

Confidence in one’s own leadership	Focus on handling leadership.

Responsibility of leadership in emergency situations and

Combining theory and practice

Developing professional knowledge	Focus on how the work strategy changes based on the competency of the colleague and the need for competence and skills development.

 	Lack of a prehospital work strategy, Supporting novices, - Being alone,Being familiar with the equipment, Seeking new knowledge and Practicing critical scenarios

Structural themes	Referential themes

To be	Focus on overview of accident

 prepared for emergency situations	site and patient and on need of feedback

To observe the situation -Ready to act Confirmation and Validation of one’s knowledge

Confidence in one’s own leadership	Focus on handling leadership.

Responsibility of leadership in emergency situations and

Combining theory and practice

Developing professional knowledge	Focus on how the work strategy changes based on the competency of the colleague and the need for competence and skills development.

	Lack of a prehospital work strategy, Supporting novices, - Being alone,Being familiar with the equipment, Seeking new knowledge and Practicing critical scenarios


 Variable	Healthy controls (n = 17)	Individuals with schizophrenia (n = 16)	t (df = 31)*	P value

Age (years)	43.65 ± 11.32	48.69 ±8.38	−1.446	.158

Gender	3 females; 14 males	4 females; 12 males	NA	NA

Education (years)	15.47± 1.81	13.00 ± 2.25	3.487	.001

Subject's SES	2.23± 1.01	3.63 1.41	−2.992	.006

Parental SES	2.54 ± 0.88	3.13 ± 1.45	−1.275	.213

Onset age (years)	NA	30.23 ± 11.95	NA	NA

Duration (years)	NA	17.15± 11.32	NA	NA

Chlorpromazine equivalent (mg)	NA	381.13 ± 247.18	NA	NA

Medication type	NA	First generation = 3 Second generation = 9	NA	NA

Positive scale PANSS	NA	23.87 ±9.41	NA	NA

Negative scale PANSS	NA	22.33± 9.56	NA	NA

General psychopathology PANSS	NA	43.00 ± 14.64	NA	NA

Total psychopathology PANSS	NA	89.20 ± 30.17	NA	NA

Variable	Healthy controls (n = 17)	Individuals with schizophrenia (n = 16)	t (df = 31)*	P value

Age (years)	43.65 ± 11.32	48.69 ±8.38	−1.446	.158

Gender	3 females; 14 males	4 females; 12 males	NA	NA

Education (years)	15.47± 1.81	13.00 ± 2.25	3.487	.001

Subject's SES	2.23± 1.01	3.63 1.41	−2.992	.006

Parental SES	2.54 ± 0.88	3.13 ± 1.45	−1.275	.213

Onset age (years)	NA	30.23 ± 11.95	NA	NA

Duration (years)	NA	17.15± 11.32	NA	NA

Chlorpromazine equivalent (mg)	NA	381.13 ± 247.18	NA	NA

Medication type	NA	First generation = 3 Second generation = 9	NA	NA

Positive scale P		23.87 ±9	N	NA

ANSS	NA	.41	A

Negative scale PANSS	NA	22.33± 9.56	NA	NA

General psychopathology PANSS	NA	43.00 ± 14.64	NA	NA

Total psychopathology PANSS	NA	89.20 ± 30.17	NA	NA


Flavonoid class	Molecular Weight	Glycosylation	Metabolic conversion	Colonic microflora

General	Decreases bioavailability	Generally removed	Major factor in bioavailability; can take place in small intestine, liver and colon; usually to glucuronides but also sulphation and methylation [39]; facilitates urinary and biliary excretion [39].	Influence availability; catabolize compounds to low molecular weight compounds that are readily absorbed [58].

Flavan-3-ols (monomeric)			Major bioactive forms: conjugates of epicatechin [41]; catechin: methyl, sulfate and glucuronic acid conjugates; epicatechin: mainly to sulfate conjugates, no glucuronidation [41].

Proanthocyanidins	Decreases bioavailability [40].		Major bioactive forms: conjugates of epicatechin [41]; oligomeric procyanidins can absorb in small intestine [51].	Influences polymeric proanthocyanidin degradation [50].

Flavonols		Sugars and their position affects bioavailability [44].	Potentially active metabolites: glucuronides [44].	Facilitates glucuronidation [60].

Anthocyanins	Anthocyanin derivatives (flavan-3-ol-anthocyanin dimer) can potentially be absorbed with less efficiency [47].	Sometimes found with sugars intact in circulation [55].	Major intestinal metabolites: glucuronide and sulfate conjugates of protocatechuic acid and phloroglucinaldehyde [46]; anthocyanin derivatives metabolically more resistant than parent compounds [47].

Isoflavones		Aglycone more bioavailable; possible deglycosylation prior hepatic metabolism [48].		Metabolize daidzein to equol [58].

Flavanones		Rapid absorption, low bioavailability [49].		Extensive first-pass metabolism partly by intestinal bacteria degraded into phenolic compounds [49].


Rabbit no.	Control collagena (absorbance)	Loaded collagen (absorbance)

1	37.8	31.8

2	29.8	28.2

3	31.1	33.0

4	42.6	38.3

5	31.0	32.1

6	39.5	37.5

Mean	35.3	33.5

SD	5.3	3.8

Significanceb


#	Name	Tag/Fusion protein, positiona and lengthb	TEV protease cleavage site	Mode of expression	EAEA repeat	Selection markerc	Plasmid size (bp)

1	PPpRSFC	–	–	–	NA	Intracellular	NA	Zeocin	4,840

2	pPpRSFC-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	5,104

3	pPpRSFC-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	5,092

4	pPpRSFC-pGAP	–	–	–	NA	Intracellular	NA	Zeocin	3,771

5	pPpRSFC-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	4,035

6	pPpRSFC-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	4,023

7	pPpRSFC-N-eGFP	eGFP	N	240	No	Intracellular	NA	Zeocin	5,584

8	pPpRSFC-C-eGFP	eGFP	C	239	No	Intracellular	NA	Zeocin	5,584

9	pPpRSFC-MFalpha-N-eGFP	eGFP	N	239	No	Secretory	Yes	Zeocin	5,848

10	pPpRSFC-MFalpha-C-eGFP	eGFP	C	239	No	Secretory	Yes	Zeocin	5,848

11	pPpRSFC-N-Myc	MYC	N	11	No	Intracellular	NA	Zeocin	4,870

12	pPpRSFC-C-Myc	MYC	C	10	No	Intracellular	NA	Zeocin	4,870

13	pPpRSFC-MFalpha-N-Myc	MYC	N	10	No	Secretory	Yes	Zeocin	5,134

14	pPpRSFC-MFalpha-C-Myc	MYC	C	10	No	Secretory	Yes	Zeocin	5,134

15	pPpRSFC-N-FLAG	FLAG	N	9	No	Intracellular	NA	Zeocin	4,864

16	pPpRSFC-C-FLAG	FLAG	C	8	No	Intracellular	NA	Zeocin	4,864

17	pPpRSFC-MFalpha-N-FLAG	FLAG	N	8	No	Secretory	Yes	Zeocin	5,128

18	pPpRSFC-MFalpha-C-FLAG	FLAG	C	8	No	Secretory	Yes	Zeocin	5,128

19	pPpRSFC-N-His-ncs	His	N	7	No	Intracellular	NA	Zeocin	4,858

20	pPpRSFC-C-His-ncs	His	C	6	No	Intracellular	NA	Zeocin	4,858

21	pPpRSFC-MFalpha-N-His-ncs	His	N	6	No	Secretory	Yes	Zeocin	5,122

22	pPpRSFC-MFalpha-C-His-ncs	His	C	6	No	Secretory	Yes	Zeocin	5,122

23	pPpRSFC-N-His	His	N	7	Yes	Intracellular	NA	Zeocin	4,879

24	pPpRSFC-C-His	His	C	6	Yes	Intracellular	NA	Zeocin	4,879

25	pPpRSFC-MFalpha-N-His	His	N	6	Yes	Secretory	Yes	Zeocin	5,143

26	pPpRSFC-MFalpha-C-His	His	C	6	Yes	Secretory	Yes	Zeocin	5,143

27	pPpRSFC-N-MBP	MBP	N	367	Yes	Intracellular	NA	Zeocin	5,959

28	pPpRSFC-C-MBP	MBP	C	366	Yes	Intracellular	NA	Zeocin	5,959

29	pPpRSFC-MFalpha-N-MBP	MBP	N	366	Yes	Secretory	Yes	Zeocin	6,223

30	pPpRSFC-MFalpha-C-MBP	MBP	C	366	Yes	Secretory	Yes	Zeocin	6,223

31	pPpRSFC-N-Strep	Strep	N	9	Yes	Intracellular	NA	Zeocin	4,885

32	pPpRSFC-C-Strep	Strep	C	8	Yes	Intracellular	NA	Zeocin	4,885

33	pPpRSFC-MFalpha-N-Strep	Strep	N	8	Yes	Secretory	Yes	Zeocin	5,149

34	pPpRSFC-MFalpha-C-Strep	Strep	C	8	Yes	Secretory	Yes	Zeocin	5,149

35	pPpRSFC-HIS	–	–	–	NA	Intracellular	NA	HIS4	7,683

36	pPpRSFC-HIS-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	7,947

37	pPpRSFC-HIS-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	7,935

38	pPpRSFC-HIS-pGAP	–	–	–	NA	Intracellular	NA	HIS4	6,614

39	pPpRSFC-HIS-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	6,878

40	pPpRSFC-HIS-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	6,866

#	Name	Tag/Fusion protein, positiona and lengthb	TEV protease cleavage site	Mode of expression	EAEA repeat	Selection markerc	Plasmid size (bp)

1	PPpRSFC	–	–	–	NA	Intracellular	NA	Zeocin	4,840

2	pPpRSFC-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	5,104

3	pPpRSFC-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	5,092

4	pPpRSFC-pGAP	–	–	–	NA	Intracellular	NA	Zeocin	3,771

5	pPpRSFC-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	4,035

6	pPpRSFC-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	4,023

7	pPpRSFC-N-eGFP	eGFP	N	240	No	Intracellular	NA	Zeocin	5,584

8	pPpRSFC-C-eGFP	eGFP	C	239	No	Intracellular	NA	Zeocin	5,584

9	pPpRSFC-MFalpha-N-eGFP	eGFP	N	239	No	Secretory	Yes	Zeocin	5,848

10	pPpRSFC-MFalpha-C-eGFP	eGFP	C	239	No	Secretory	Yes	Zeocin	5,848

11	pPpRSFC-N-Myc	MYC	N	11	No	Intracellular	NA	Zeocin	4,870

12	pPpRSFC-C-Myc	MYC	C	10	No	Intracellular	NA	Zeocin	4,870

13	pPpRSFC-MFalpha-N-Myc	MYC	N	10	No	Secretory	Yes	Zeocin	5,134

14	pPpRSFC-MFalpha-C-Myc	MYC	C	10	No	Secretory	Yes	Zeocin	5,134

15	pPpRSFC-N-FLAG	FLAG	N	9	No	Intracellular	NA	Zeocin	4,864

16	pPpRSFC-C-FLAG	FLAG	C	8	No	Intracellular	NA	Zeocin	4,864

17	pPpRSFC-MFalpha-N-FLAG	FLAG	N	8	No	Secretory	Yes	Zeocin	5,128

18	pPpRSFC-MFalpha-C-FLAG	FLAG	C	8	No	Secretory	Yes	Zeocin	5,128

19	pPpRSFC-N-His-ncs	His	N	7	No	Intracellular	NA	Zeocin	4,858

20	pPpRSFC-C-His-ncs	His	C	6	No	Intracellular	NA	Zeocin	4,858

21	pPpRSFC-MFalpha-N-His-ncs	His	N	6	No	Secretory	Yes	Zeocin	5,122

22	pPpRSFC-MFalpha-C-His-ncs	His	C	6	No	Secretory	Yes	Zeocin	5,122

23	pPpRSFC-N-His	His	N	7	Yes	Intracellular	NA	Zeocin	4,879

24	pPpRSFC-C-His	His	C	6	Yes	Intracellular	NA	Zeocin	4,879

25	pPpRSFC-MFalpha-N-His	His	N	6	Yes	Secretory	Yes	Zeocin	5,143

26	pPpRSFC-MFalpha-C-His	His	C	6	Yes	Secretory	Yes	Zeocin	5,143

27	pPpRSFC-N-MBP	MBP	N	367	Yes	Intracellular	NA	Zeocin	5,959

28	pPpRSFC-C-MBP	MBP	C	366	Yes	Intracellular	NA	Zeocin	5,959

29	pPpRSFC-MFalpha-N-MBP	MBP	N	366	Yes	Secretory	Yes	Zeocin	6,223

30	pPpRSFC-MFalpha-C-MBP	MBP	C	366	Yes	Secretory	Yes	Zeocin	6,223

31	pPpRSFC-N-Strep	Strep	N	9	Yes	Intracellular	NA	Zeocin	4,885

32	pPpRSFC-C-Strep	Strep	C	8	Yes	Intracellular	NA	Zeocin	4,885

33	pPpRSFC-MFalpha-N-Strep	Strep	N	8	Yes	Secretory	Yes	Zeocin	5,149

34	pPpRSFC-MFalpha-C-Strep	Strep	C	8	Yes	Secretory	Yes	Zeocin	5,149

35	pPpRSFC-HIS	–	–	–	NA	Intracellular	NA	HIS4	7,683

36	pPpRSFC-HIS-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	7,947

37	pPpRSFC-HIS-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	7,935

3	pPpRSFC-HIS-pGAP	–		–	N	Intracellu	NA	H	6,614

#	Name	Tag/Fusion protein, positiona and lengthb	TEV protease cleavage site	Mode of expression	EAEA repeat	Selection markerc	Plasmid size (bp)

8			–		A	lar		IS4

39	pPpRSFC-HIS-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	6,878

40	pPpRSFC-HIS-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	6,866


Characteristic	Value

Total number	35

Median age (IQR) in months	20 (16–22)

Females (%)	19 (54%)

Median children in household (range)	3 (1–6)

Smokers in household (%)	11 (31%)

Received 3 doses of pentavalent vaccine	91.4%

Received at least 1 dose of pentavalent vaccine	100.0%


#	Assumption

1	There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012)

2	Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys

3	The urinary excretion (Qurine) is similar for all compounds

4	Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data

5	The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules

6	The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012)

7	All rate equations are to be described as mass action law

#	Assumption

1	There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012)

2	Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys

3	The urinary excretion (Qurine) is similar for all compounds

4	Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data

5	The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules

	The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler

6	et al., 2012)

7	All rate equations are to be described as mass action law


	MOCOS

c.1881delG /c.1782delG

	G/G	G/del	del/del

Affected animals			4

Obligate carriers		3

Tyrolean Grey population controls	1151	50

Controls of other breedsa	1225

Total	2376	53	4

	MOCOS

c.1881delG /c.1782delG

	G/G	G/del	del/del

Obligate carriers		3

Tyrolean Grey population controls	1151	50

Controls of other breedsa	1225

Total	2376	53	4


Health Claims (Dedicated Children’s Channels)	2010 (%)	% Change v 2008 (+/−)	2010 All Channels (%)

Contains essential nutrients e.g., calcium, vitamins, antioxidants	39.7	+29	33.4

Part of your five a day	28.9	+4.9	10.3

Organic	10.4	+8.8	5.0

Wholegrain	8.3	−11.8	7.8

Low fat	4.7	+2.8	9.8

No added sugar	3.7	−0.5	2.1

Contains only natural ingredients	3.1	−12.2	15.9

Contains fibre	0.6	+0.6	1.3

Is low calorie/light	0.6	−5.1	5.1

Health Claims (Dedicated Children’s Channels)	2010 (%)	% Change v 2008 (+/−)	2010 All Channels (%)

Contains fibre	0.6	+0.6	1.3

Is low calorie/light	0.6	−5.1	5.1


Configuration	Packets Received per Second

CSR1	CSR2	CSR3	Average

CSR devices transmit each packet one	0.62	1.41	1.08	1.04

CSR devices transmit each packet three times	1.16	1.76	1.91	1.61

Configuration	Packets Received per Second

CSR1	CSR2	CSR3

CSR devices transmit each packet one	0.62	1.41	1.08

CSR devices transmit each packet three times	1.16	1.76	1.91

Packets Received per Second

Average

1.04

1.61


Surface	Contact angle (deg.)	Contact angle hysteresis (deg.)	Sliding angle (deg.)

TO-SHS	169±4	45±15	>45

TO-SLIPS	124±1	1.4±0.5	3.0±0.3

Surface	Contact angle (deg.)	Contact angle hysteresis (deg.)	Sliding angle (deg.)

TO-SLIPS	124±1	1.4±0.5	3.0±0.3


Dose (mg kg−1)	Fatty change	Hydropic swelling	Mild inflammation	Mild fibrosis

Saline	0/4	0/4	0/4	0/4


Pool	DMRs (Number)	DMRs (%)

Bulgarian females (patients/controls)	293	1.1

Bulgarian males (patients/controls)	948	3.4

Serbian females (patients/controls)	947	3.4

Serbian males (patients/controls)	944	3.4

Pool	s (Number)	s (%)

Bulgarian females (patients/controls)	293	1.1

Bulgarian males (patients/controls)	948	3.4

Serbian females (patients/controls)	947	3.4

Serbian males (patients/controls)	944	3.4


Author	Patient (n) (age/sex)	Procedure	Cardiac rhythm	Cause	Management	Outcome

Chowdhury and West [3]	50 y ♀	Awake craniotomy (frontal tumor)	Bradycardia, asystole (25 s)	TCR (scalp traction)	Release scalp traction; cessation propofol and remifentanil infusions	No neurological deficit

Prabhu et al. [4]	65 y ♂	Awake craniotomy (temporal tumor) 	Bradycardia and asystole (8–10 s × 2 times)	TCR (dura cautery)	Cessation of cautery, atropine	No neurological deficit

Sinha et al. [5]	18 y ♂	Epilepsy surgery 	Bradycardia (2 episodes), asystole (9 s)	↑Parasympathetic response 2° to amygdala resection; warm and cold saline irrigation	Atropine; cessation of stimulus	No neurological deficit

Sato et al. [6]	6/42 [18–34 y; ♀ = 3, ♂ = 2]	Epilepsy surgery	Sinus bradycardia (<1 min)	↑Parasympathetic tone 2° to limbic stimulation	Procedure interruption; atropine	No neurological deficit

Tyler et al. [7]	22 y ♀	Craniotomy (parietal tumor)	Asystole	Intracranial hematoma (dural closure)	Hematoma evacuation	No neurological deficit

Wasnick et al. [8]	70 ♂	Epidural suction drain	Severe bradycardia	Intracranial hypotension	Release of suction	No neurological deficit

Alfery et al. [9]	18 ♀	VP shunt	VT, VF	Intracranial hypotension	Lidocaine, CPR	No neurological deficit

Karamchandani et al. [10]	65 ♀	Subgaleal suction drain	Multiple severe bradycardia	Intracranial hypotension	Release of suction, atropine	No neurological deficit

Bhagat et al. [11]	2 patients[both 60 ♂]	Subgaleal suction drain	Severe bradycardia, Asystole	Intracranial hypotension	Release of suction, atropine	No neurological deficit


Method	Rank	Rank	TPR in top	TPR in top	TPR in top	TPR in top	AUC	Rank difference

	median	average	1% (%)	5% (%)	10% (%)	30% (%)		p-value

Genome-wide prioritizations

Scuba	8.13	17.45 ± 22.33	10.4	41.7	58.3	79.2	0.83	-

MKL1class [12]	14.28	25.79 ± 26.96	2.1	27.1	45.8	66.7	0.74	1.2 ·10−5 *

Method	Rank	Rank	TPR in top	TPR in top	TPR in top	TPR in top	AUC	Rank difference

	median	average	1% (%)	5% (%)	10% (%)	30% (%)		p-value

ProDiGe [13]	7.89	18.40 ± 23.77	10.4	43.8	54.2	79.2	0.82	9.5 ·10−2


	Mean (SD)	P value

	1st trimester	2nd trimester	3rd trimester

Completion time (minutes)	21.8 (7.5)	19.2 (6.8)	16.3 (5.1)	< 0.0001

Reported meals (N)	5.1 (0.9)	4.8 (1.1)	5.0 (1.2)	0.13

Repor	20.5 (	20.	19.	0.0


Complications	Group 1	Group 2

To adult	To pediatrics	En-bloc	Single

Renal vein thrombosis	—	1 (early nephrectomy)	—	2 (graft loss)

Renal arterial thrombosis	1 (graft loss)	—	—	—

Significant lymphocele	1 (percutaneous drainage)	—	1 (percutaneous drainage)	1

Ureteral fistula	1 (surgical repair)	—	—	1 (surgical repair)

Ureteral stenosis	1 (surgical repair)	—	—	1 (surgical repair)


	n of cases	IPAT	PSP	IPAT & PSP

CF and RP/CP	48	14 (29.2)	11 (22.9)	19 (39.6)


Gene	F/R	Primer sequence	Position	Tm

PEPT1	Forward	CCCTGAAGTGAAGGTGTTTGAAGATA	1772–1797	60.6

NM_005073	Reverse	GAATTGGCCCCTGACATGAA	2168–2188	59.3

PEPT2	Forward	CTACCACAATATGCCCTGGTTACA	1894–1917	58.8

NM_001145998	Reverse	GCCACTGAACTGTGCCACAA	2045–2064	59.3

ALAS1	Forward	GGATTCGAAACAGCCGAGTG	1371–1390	59.3

NM 000688	Reverse	GAAGGTGATTGCTCCAAACTCAT	1542–1564	58.3

ALAD	Forward	CCTCGGTTCCAACCAACTGAT	157–177	59.8

NM_000031	Reverse	GATAGGCTGTATGTCATCAGGAACA	319–343	58.2

HMBS	Forward	CAAGGACCAGGACATCTTGGAT	835–856	58.9

NM_000190	Reverse	CCAGACTCCTCCAGTCAGGTACA	984–1006	59.2

UROS	Forward	TCAGCACTGCCTCTTCTATTTCC	668–691	58.7

NM_000375	Reverse	CTGGGTGTGCAACTGTCTGATAC	761–789	58.3

UROD	Forward	CGGGAGTGTGTGGGGAA	982–998	57.2

NM_000374	Reverse	AAGCAGACGTGAGTGTTTATGCA	1178–1200	58.6

ABCB6	Forward	CAGAAGGGCCGTATTGAGTTTG	2033–2054	59.6

NM_005689	Reverse	ATTGTCGGCGATGGTGTCA	2308–2326	59.5

CPOX	Forward	GGCGGAGATGTTGCCTAAGAC	401–421	59.7

NM_000097	Reverse	AATGCTCACCCCAGCCTTTT	709–728	59.5

PPOX	Forward	CAGGAGTCCTGGGAATCGTGTA	1251–1272	59.9

NM_000309	Reverse	TGCCTAGCTGACTCTAGTTTTTGC	1509–1533	58.1

FECH	Forward	GGAAATCCATTGTTCTCTAAGGC	1252–1274	57.0

NM_001012515	Reverse	CTAAATAACACCCTCTCCACATCG	1462–1485	57.8

ABCG2	Forward	CTAAGCAGGGACGAACAATCATC	1188–1210	58.8

NM_004827	Reverse	TCCTGCTTGGAAGGCTCTATG	1447–1467	58.2

HIF-1alpha	Forward	GGCGCGAACGACAAGAA	420–436	58.0

NM 001530	Reverse	CAAAACCATCCAAGGCTTTCA	682–702	58.7

HO-1	Forward	GCTCAAAAAGATTGCCCAGAA	518–538	58.1

NM_002133	Reverse	TCACATGGCATAAAGCCCTACA	926–947	59.1

Gene	F/R	Primer sequence	Position	Tm

NM_001012515	Reverse	CTAAATAACACCCTCTCCACATCG	1462–1485	57.8

ABCG2	Forward	CTAAGCAGGGACGAACAATCATC	1188–1210	58.8

NM_004827	Reverse	TCCTGCTTGGAAGGCTCTATG	1447–1467	58.2

HIF-1alpha	Forward	GGCGCGAACGACAAGAA	420–436	58.0

NM 001530	Reverse	CAAAACCATCCAAGGCTTTCA	682–702	58.7

HO-1	Forward	GCTCAAAAAGATTGCCCAGAA	518–538	58.1

NM_002133	Reverse	TCACATGGCATAAAGCCCTACA	926–947	59.1


	Pain score ribs	Pain score iliac crest

Hospital admission, oral analgesics	5	Not applicable

Pre-operative, with epidural catheter	3-6	Not applicable

Post-operative day 3, with epidural catheter	1-2	4-5

Discharge home, oral analgesics	1-2	3-5

	Pain score ribs	Pain score iliac crest

Pre-operative, with epidural catheter	3-6	Not applicable

Post-operative day 3, with epidural catheter	1-2	4-5

Discharge home, oral analgesics	1-2	3-5


 	Vascularization ≤ 1 point

No	Yes

Target IOP not reached	No	39	3

Yes	10	5

Agreement	Kappa	 	.31


Assembler	Sequencing	Strains	Insert size	Read length (bp)	Number of reads	Raw read coverage	Assembled bases (Mb)	Contig coverage	Contig N50

FuzzyPath	Illumina	CAST/Ei	200 bp	36	173 million	65×	76.03	80.0%	2,315

Velvet*	Illumina	CAST/Ei	200 bp	36	173 million	65×	58.09	61.15%	391

ABySS	Illumina	CAST/Ei	200 bp	36	173 million	65×	72.80	76.63%	1,022

FuzzyPath	Illumina	A/J	200 bp	36	112 million	42×	55.87	58.8%	959

Phusion	Capillary	A/J	3-5 kb	400-900	357,100	2.5×	81.2	85.5%	3,377

FuzzyPath	Hybrid	A/J†	Hybrid†	Hybrid†	Hybrid†	Hybrid†	85.54	90.0%	5,793


	Infant HIV exposure category	p-Valueb

HEU (N = 60)	HUU (N = 72a)

Maternal characteristics

Mean (SD) maternal age at enrollment	28.0 (5.1)	25.9 (6.2)	0.05

Substance use during pregnancy, N (%)

Alcohol	13 (21.7)	8 (11.1)	0.15

Tobacco	16 (26.7)	10 (13.9)	0.08

Marijuana	4 (6.7)	0 (0.0)	0.04

Crack or cocaine	2 (3.3)	0 (0.0)	0.20

Maternal employment, N (%)	22 (36.7)	41 (56.9)	0.02

Mean (SD) years of completed education	7.6 (3.2)	9.3 (2.4)	0.001

Mean (SD) number of prior pregnancies	2.3 (1.9)	1.2 (1.3)	<0.0001

Mean (SD) parity	1.8 (1.6)	1.0 (1.1)	0.001

Mean (SD) number of people living in the household	4.4 (2.0)	4.7 (1.7)	0.32

Mean (SD) CD4 count (cells/mm3) at hospital discharge	563.9 (266.7)	–	–

Mean (SD) CD4% at hospital discharge	32.0 (9.4)	–	–

Mean (SD) viral load (log10 copies/mL) at hospital discharge	2.23 (0.81)	–	–

Viral load <400 copies/mL at hospital discharge, N (%)	51 (85.0)	–	–

ARV use during pregnancy, N (%)		–	–

Zidovudine monotherapy	25 (41.7)	–	–

Combination antiretrovirals	35 (58.3)

Infant characteristics

Mean (SD) gestational age at birth (weeks)	38.7 (1.2)	39.2 (1.4)	0.01

Female gender, N (%)	25 (41.8)	36 (50.0)	0.38

Mean (SD) birth weight (g)	3176.4 (381.5)	3346.5 (422.7)	0.02

Small for gestational age (<10th percentile), N (%)	2 (3.3)	0 (0.0)	0.20

Large for gestational age (>90th percentile), N (%)	7 (11.7)	16 (22.2)	0.17

Not breastfeeding, N (%)	60 (100)	1 (1.4)	<0.0001


SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS	TREATMENT GROUP(N = 22)MEAN ± SD	WAITING LIST CONTROL GROUP (N = 24)MEAN ± SD	P

Age (years)	48.6 ± 11.2	53.0 ± 11.4	0.20

Sex (F/M)	15/7	20/4	0.27

BMI (kg/m2)	24.9 ± 4.0	24.1 ± 3.1	0.47

Pain at rest (PR)	45.5 ± 20.9	42.3 ± 18.0	0.58

Duration of neck pain (years)	6.3 ± 6.1	8.0 ± 7.6	0.41

Expected effectiveness of cupping therapy(VAS from 0 = not effective at all to 100 = highly effective)	82.8 ± 13.6	72.4 ± 21.3	0.06


Patient no. (with cartilage damage)	Teres ligament	Joint capsule

 	S100	Substance P	S100	Substance P

1.	+	+	-	-

4.	-	+	+	-

5.	+	+	+	+

9.	+	+	-	-

11.	+	+	+	+

12.	+	+	-	-

15.	+	+	-	-

16.	+	+	+	-

17.	-	-	-	+

Patient no. (with cartilage damage)	Teres ligament	Joint capsule

	S100	Substance P	S100	Substance P

1.	+	+	-	-

4.	-	+	+	-

5.	+	+	+	+

9.	+	+	-	-

11.	+	+	+	+

12.	+	+	-	-

15.	+	+	-	-

	+	+		-

Patient no. (with cartilage damage)	Teres ligament	Joint capsule

	S100	Substance P	S100	Substance P

16.			+

17.	-	-	-	+


Extracted peatland drains

Linear validation dataset	Drain	No drain		Total	Producer accuracy

Drain	193	131		324	0.60

No drain	39	2637		2676	0.99

			2830

Total	232	2768		3000

User accuracy	0.83	0.95

Kappa statistic	0.66			OA	0.94


Genes	Identity	Major function

Genes that promote neuronal integrity during aging

daf-16	FoxO transcription factor	Upregulation of stress resistance genes

hsf-1	Heat shock transcription factor	Upregulation of small heat shock protein expression

mec-1	EGF and Kunitz domain-containing ECM protein	Mechanosensory transduction, nerve attachment

mec-2	Stomatin-like	Mechanosensory transduction

mec-4	DEG/ENaC family sodium channel	Mechanosensory transduction

mec-5	Atypical collagen	Mechanosensory transduction, nerve attachment

mec-6	Paraoxonase	Mechanosensory transduction

mec-9	EGF and Kunitz domain-containing ECM protein	Mechanosensory transduction, nerve attachment

mec-10	DEG/ENaC family sodium channel	Mechanosensory transduction

mec-12	α-tubulin	Mechanosensory transduction, axon transport

jkk-1	JNK kinase	Activation of JNK; synaptic vesicle localization

jnk-1	c-Jun N-terminus kinase (JNK)	Heat and stress response; locomotion

mek-1	Mitogen activated protein kinase (MAPK) kinase/MKK7	Stress and starvation response

lmn-1	Laminin	Regulation of nuclear organization and function

ptl-1	Tau/microtubules-associated protein	Microtubule stabilization?

unc-13	Munc-13	Synaptic vesicle fusion

unc-18	Munc-18	Synaptic vesicle docking

Genes that accelerate neuronal aging

daf-2	Insulin-like growth factor receptor	Larval development, dauer formation, etc

dgk-1	Diacylglycerol kinase	Inhibition of synapse transmission

slo-1	BK-type potassium channel	Muscle inactivation, neuronal excitability, etc


Ribosomal protein gene	Chromosomal assignment in C. elegans	Number of 5' codons omitted from analysis	Coding nucleotides used for analysis

rpl-1	III	3	642

rpl-2	V	0	783

rpl-10	II	5	630

rpl-14	I	5	402

rpl-16	III	5	597

rpl-23	III	5	408

rpl-26	II	3	423

rpl-27	I	6	393

rpl-27a	I	8	420

rpl-28	V	7	387

rpl-29	IV	0	189

rpl-30	I	4	339

rpl-31	I	8	345

rpl-32	II	8	381

rpl-34	IV	4	330

rpl-35	III	8	348

rpl-38	V	6	195

rpl-39	V	8	132

rps-1	III	6	762

rps-8	IV	3	618

rps-14	III	8	435

rps-20	I	0	357

rps-21	III	0	267

rps-24	IV	0	396

rps-25	IV	7	336

rps-27	V	0	255

rps-28	IV	0	201

Total number of nucleotides:			10,971

Ribosomal protein gene	Chromosomal assignment in C. elegans	Number of 5' codons omitted from analysis	Coding nucleotides used for analysis

rps-21	III	0	267

rps-24	IV	0	396

rps-25	IV	7	336

rps-27	V	0	255

rps-28	IV	0	201

Total number of nucleotides:			10,971


Primary antibody	Manufacturer	Cat. number	Dilution	Source

OCT4	Abcam	ab18976	1/250	Rabbit

NANOG	Abcam	ab21624	1/100	Rabbit

SSEA4	Abcam	ab16287	1/100	Mouse

TRA-1-81	Abcam	ab16289	1/100	Mouse

TRA-1-60	Abcam	ab16288	1/100	Mouse

SOX1	Abcam	ab87775	1/200	Rabbit

PAX6	DSHB	3B5	1/50	Mouse

OTX2	Abcam	ab21990	1/500	Rabbit

LHX2	Santa Cruz Biotechnology	sc-81311	1/200	Mouse

SIX3	Rockland	600-401-A26	1/500	Rabbit

MCM2	Abcam	ab4461	1/400	Rabbit

CHX10	Millipore	ab9016	1/200	Sheep

FIBRONECTIN	Abcam	ab2413	1/200	Rabbit

ZO-1	Thermo Fisher	33-9100	1/400	Mouse

BRN3	Santa Cruz Biotechnology	sc-6026	1/200	Goat

AP2	DSHB	3B5a	1/35	Mouse

PROX1	Abcam	ab101851	1/2000	Rabbit

PKC-α	Abcam	ab32376	1/2000	Rabbit

CRALBP	Abcam	ab15051	1/500	Mouse

Rhodopsin	Abcam	ab3267	1/200	Mouse

S opsin	Gift from Dr. Jeremy Nathans	/	1/5000	Rabbit

L/M opsin	Gift from Dr. Jeremy Nathans	/	1/5000	Rabbit

Recoverin	Millipore	ab5585	1/500	Rabbit

PDE6α	Abcam	ab5665	1/100	Rabbit

Gtα-1	Santa Cruz Biotechnology	sc-136143	1/2000	Mouse


	Males N (%)	Females N (%)	Age in years median (Range)

Sindh	38 (62%)	23 (38%)	28 (0.3 to 65)


Task	Satisfactory	Unsatisfactory

(1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP).	—	—

(2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing solution are present. 	—	—

(3) Palpates the superior aspects of the iliac crests and identifies the intersection at the L4 spinous process with nonsterile gloves on. Marks position at the L3/L4 or L4/L5 interspace.	—	—

(4) Cleans the overlying skin with chlorhexidine.	—	—

(5) Opens the spinal tray before placing sterile gloves on.	—	—

(6) Puts on sterile gloves with proper technique.	—	—

(7) Applies sterile drapes.	—	—

(8) Draws up lidocaine in the 3cc syringe and bupivacaine in the 5cc syringe. Administers local anesthesia in a wheal at the previously marked site.	—	—

(9) Injects more anesthetic in the correct location and angle.	—	—

(10) Inserts the introducer needle in the middle of the interspace with a slight cephalad angulation of 10 to 15 degrees. The bevel of the spinal needle should be in the sagittal plane.	—	—

(11) Advances spinal needle through anatomic structures until the subarachnoid space is reached. May experience a popping sensation as the ligamentum flavum is crossed.	—	—

(12) Withdraws the stylet each time a pop is felt to assess for CSF flow.	—	—

(13) Confirms CSF flow by aspiration before and after injecting anesthetic.	—	—

(14) Removes the spinal and introducer needle together once completed. 	—	—

(15) Applies pressure with the provided 2 × 2 gauze and assesses good hemostasis.	—	—

(16) Removes the drape, lays the patient, and observes vitals. Disposes of all sharps and biohazard material appropriately. 	—	—

Task	Satisfactory

(1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP).	—

(2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing solution are present.	—

(3) Palpates the superior aspects of the iliac crests and identifies the intersection at the L4 spinous process with nonsterile gloves on. Marks position at the L3/L4 or L4/L5 interspace.	—

(4) Cleans the overlying skin with chlorhexidine.	—

(5) Opens the spinal tray before placing sterile gloves on.	—

(6) Puts on sterile gloves with proper technique.	—

(7) Applies sterile drapes.	—

(8) Draws up lidocaine in the 3cc syringe and bupivacaine in the 5cc syringe. Administers local anesthesia in a wheal at the previously marked site.	—

(9) Injects more anesthetic in the correct location and angle.	—

(10) Inserts the introducer needle in the middle of the interspace with a slight cephalad angulation of 10 to 15 degrees. The bevel of the spinal needle should be in the sagittal plane.	—

(11) Advances spinal needle through anatomic structures until the subarachnoid space is reached. May experience a popping sensation as the ligamentum flavum is crossed.	—

(12) Withdraws the stylet each time a pop is felt to assess for CSF flow.	—

(13) Confirms CSF flow by aspiration before and after injecting anesthetic.	—

(14) Removes the spinal and introducer needle together once completed.	—

(15) Applies pressure with the provided 2 × 2 gauze and assesses good hemostasis.	—

(16) Removes the drape, lays the patient, and observes vitals. Disposes of all sharps and biohazard material appropriately.	—

Unsatisfactory

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—


		KEGG pathway	Count	P value

HFF1_24 h vs HFF1	Up-regulated gene	hsa04622: RIG-I-like receptor signaling pathway	6	9.35E-05

hsa04620: Toll-like receptor signaling pathway	5	0.0043

hsa04623: Cytosolic DNA-sensing pathway	4	0.0057

HFF1_48 h vs HFF1	Up-regulated gene	hsa04620: Toll-like receptor signaling pathway	6	0.0209

hsa04622: RIG-I-like receptor signaling pathway	5	0.0249

Down-regulated gene	hsa05410: Hypertrophic cardiomyopathy (HCM)	4	0.0479

HFF1_72 h vs HFF1	Up-regulated gene	hsa00330: Arginine and proline metabolism	6	0.0076

hsa00480: Glutathione metabolism	5	0.0287

hsa00250: Alanine, aspartate and glutamate metabolism	4	0.0349

Down-regulated gene	hsa04510: Focal adhesion	13	4.57E-05

hsa04810: Regulation of actin cytoskeleton	10	0.0056

hsa05200: Pathways in cancer	11	0.0272

ES vs HFF1	Up-regulated gene	hsa05217: Basal cell carcinoma	14	9.58E-06

hsa04310: Wnt signaling pathway	22	1.28E-04

hsa05200: Pathways in cancer	36	2.29E-04

hsa00330: Arginine and proline metabolism	10	0.0029

Down-regulated gene	hsa04510: Focal adhesion	40	8.73E-08

hsa00520: Amino sugar and nucleotide sugar metabolism	13	1.09E-04

hsa04512: ECM-receptor interaction	18	2.52E-04

hsa04142: Lysosome	20	0.0019

iPS vs HFF1	Up-regulated gene	hsa04310: Wnt signaling pathway	16	2.39E-04

hsa05217: Basal cell carcinoma	8	0.0029

hsa00250: Alanine, aspartate and glutamate metabolism	6	0.0041

hsa00260: Glycine, serine and threonine metabolism	6	0.0041

Down-regulated gene	hsa04510: Focal adhesion	56	1.46E-11

hsa04512: ECM-receptor interaction	27	3.06E-07

hsa00520: Amino sugar and nucleotide sugar metabolism	16	2.84E-05

hsa04810: Regulation of actin cytoskeleton	42	1.43E-04

HFF1_72 h vs HFF1	Up-regulated gene	hsa00250: Alanine, aspartate and glutamate metabolism	4	0.0349

Down-regulated gene	hsa04510: Focal adhesion	13	4.57E-05

hsa04810: Regulation of actin cytoskeleton	10	0.0056

hsa05200: Pathways in cancer	11	0.0272

ES vs HFF1	Up-regulated gene	hsa05217: Basal cell carcinoma	14	9.58E-06

hsa04310: Wnt signaling pathway	22	1.28E-04

hsa05200: Pathways in cancer	36	2.29E-04

hsa00330: Arginine and proline metabolism	10	0.0029

Down-regulated gene	hsa04510: Focal adhesion	40	8.73E-08

hsa00520: Amino sugar and nucleotide sugar metabolism	13	1.09E-04

hsa04512: ECM-receptor interaction	18	2.52E-04

hsa04142: Lysosome	20	0.0019

iPS vs HFF1	Up-regulated gene	hsa04310: Wnt signaling pathway	16	2.39E-04

hsa05217: Basal cell carcinoma	8	0.0029

hsa00250: Alanine, aspartate and glutamate metabolism	6	0.0041

hsa00260: Glycine, serine and threonine metabolism	6	0.0041

Down-regulated gene	hsa04510: Focal adhesion	56	1.46E-11

hsa04512: ECM-receptor interaction	27	3.06E-07

hsa00520: Amino sugar and nucleotide sugar metabolism	16	2.84E-05

hsa04810: Regulation of actin cytoskeleton	42	1.43E-04


Author (reference number)	Gender	GA (wks)	Clinical features of LCH involvement	Outcome (survival)

Vade et al. [10]	F	35	Skin, hepatosplenomegaly, pulmonary failure	Died (9 days)

Gee et al. [11]	M	33	Skin, pulmonary failure	Died (36 hrs)

Aviner et al. [12]	F	32	Skin, followed by multiorgan failure	Died (26 days)

Lee et al. [8]	M	36	Hydrops fetalis, skin, multiorgan failure	Died (12 days)

Cheng et al. [9]	M	33	Hydrops fetalis, skin, pleural effusion	Died (36 hrs)

Herbrüggen et al. [13]	M	35	Skin, at 3 months, pulmonary and thymic mass	Alive

Present case	F	33	Skin, hypovolemic shock, pulmonary failure	Died (57 hrs)

Author (reference number)	Gender	GA (wks)	Clinical features of LCH involvement	Outcome (survival)

Vade et al. [10]	F	35	Skin, hepatosplenomegaly, pulmonary failure	Died (9 days)

Gee et al. [11]	M	33	Skin, pulmonary failure	Died (36 hrs)

Aviner et al. [12]	F	32	Skin, followed by multiorgan failure	Died (26 days)

Lee 	M		Hydrops fetalis, skin, multiorgan fa	Died

et al. [8]		36	ilure	(12 days)

Cheng et al. [9]	M	33	Hydrops fetalis, skin, pleural effusion	Died (36 hrs)

Herbrüggen et al. [13]	M	35	Skin, at 3 months, pulmonary and thymic mass	Alive

Present case	F	33	Skin, hypovolemic shock, pulmonary failure	Died (57 hrs)


	Ontology 8a – Regex	Ontology 7b – Voting

Total number of top-level terms	662		1886

Number of sampled top-level terms	200	30.2% of total	200	10.6% of total

Number of sampled top-level terms relevant to animal behaviour	84	42% of sample	82	41% of sample

Proportionate number of top- level animal behaviour terms in the whole ontology	278		773

Number of sampled top-level an imal behaviour terms not found in the other ontology	44	22% of sample	77	38.5% of sample

Proportionate number of top- level animal behaviour terms in the whole ontology not found in the other ontology	145		727

	Ontology 8a – Regex

Total number of top-level terms	662

Number of sampled top-level terms	200

Number of sampled top-level terms relevant to animal behaviour	84

Proportionate number of top- level animal behaviour terms in the whole ontology	278

Number of sampled top-level an imal behaviour terms not found in the other ontology	44

Proportionate number of top- level animal behaviour terms in the whole ontology not found in the other ontology	145

Ontology 8a – Regex	Ontology 7b – Voting

	1886

30.2% of total	200	10.6% of total

42% of sample	82	41% of sample

	773

22% of sample	77	38.5% of sample

	727


Parameters	Group

	Control diet	5% CL diet	10% CL diet

in (ng/mL)	.23	0.18	1.79 ± 0.31

Adiponectin (ng/mL)	3.58 ± 0.11	3.51 ± 0.15	3.30 ± 0.13


Variables	ALL N=383	Right hemiparesis 208 (54%)	Left hemiparesis 157 (41%)	Bilateral hemipareses 18 (5%)	P-Value

mean±SD, n (%)

Age in years	54.9±15.3	58.8±16.4	57.9±14.8	47.9±14.7	0.019

Gender

Male	213(56)	124(60)	82(52)	7(39)	0.13

Female	170(44)	84(40)	75(48)	11(61)

Discharge disposition


P-Value3	P-Value2	Control Group	P- Value1	After Treatment	Before Treatment

*	002*	97.54±66.04	56*	31	54.66±31.50	L-1α


	Super-obese group	Comparison	OR	AORb

(N = 370)	(N = 621)

%	%

Complications during pregnancy

Me		13	3.35 (2.43–4.62	2.89


Composites	Relatives items

Parental sensitivity	Acknowledging; imitating; elaborating; parent gaze; positive affect; vocal appropriateness, clarity; appropriate range of affect; resourcefulness; praising; affectionate touch; supportive presence; infant led interaction

Parent intrusiveness	Forcing-physical manipulation; overriding, intrusiveness; parent negative affect, anger; parent anxiety; criticizing; parent-led interaction

Parent limit setting	Consistency of style; resourcefulness; appropriate structure, limit setting

Child compliance	Compliance to parent; reliance on parent for help; on-task persistence

Child withdrawal	Child negative emotionality, fussy; withdrawal; labile affect; avoidance of parent

Child engagement	Joint attention; child positive affect; affection to parent; alertness; fatigue; vocalizations, verbal output; initiation; competent use of the environment; creative-symbolic play; infant-led interaction

Dyadic joint negative state	Parent negative affect, anger; hostility; child negative emotionality, fussy; withdrawal, labile affect; fatigue; constriction; tension

Dyadic reciprocity	Parent gaze; positive affect; praising; affectionate touch; joint attention; child positive affect; vocalization, verbal output; initiation; dyadic reciprocity; adaptation-regulation; fluency

Composites	Relatives items

Child engagement	Joint attention; child positive affect; affection to parent; alertness; fatigue; vocalizations, verbal output; initiation; competent use of the environment; creative-symbolic play; infant-led interaction

Dyadic joint negative state	Parent negative affect, anger; hostility; child negative emotionality, fussy; withdrawal, labile affect; fatigue; constriction; tension

Dyadic reciprocity	Parent gaze; positive affect; praising; affectionate touch; joint attention; child positive affect; vocalization, verbal output; initiation; dyadic reciprocity; adaptation-regulation; fluency


PRISMA statement results

			Yes	Partial	No

Title	1	Title	221	(93%)	13	(5%)	2	(0%)

Abstract	2	Structured summary	82	(35%)	147	(62%)	7	(3%)

Introduction	3	Rationale	233	(98%)	3	(1%)	0	(0%)

Methods	4	Objectives	143	(60%)	90	(38%)	3	(1%)

	5	Protocol and registration	2	(1%)	35	(15%)	199	(84%)

	6	Eligibility criteria	209	(88%)	27	(11%)	0	(0%)

	7	Information sources	235	(99%)	1	(0%)	0	(0%)

		Se	59	(25%	177	(75%)	0	(0


Difference	PSF + TOF vs. PSF	3D-OSEM + TOF vs. 3D-OSEM

Low TBR	High TBR	Low TBR	High TBR

	**	n.s.	**	n.s.

Median	10.4	1.8	8.6	−0.1

IQR	3.1 to 19.0	−0.8 to 5.5	3.3 to 14.8	−6.0 to 2.4

Range	1.0 to 27.2	−16.7 to 27.9	−5.9 to 17.5	−13.9 to 24.0


Cell line	Gq mutant	G11 mutant	BRAF mutant

Melanocytes	WT	WT	WT

OCM1	WT	WT	V600E

OCM3	WT	WT	V600E

OMM1	WT	Q209L	WT

OMM2.3*	Q209P	WT	WT

Mel270*	Q209P	WT	WT

LOXIMVI	WT	WT	V600E

M14	WT	WT	V600E

MALME-3M	WT	WT	V600E

MDA-MB-435	WT	WT	V600E

SK-MEL-2	WT	WT	V600E

SK-MEL-28	WT	WT	V600E

SK-MEL-5	WT	WT	V600E

ACC-257	WT	WT	V600E

UACC-62	WT	WT	V600E

Cell line	Gq mutant	G11 mutant

Melanocytes	WT	WT

OCM1	WT	WT

OCM3	WT	WT

OMM1	WT	Q209L

OMM2.3*	Q209P	WT

Mel270*	Q209P	WT

LOXIMVI	WT	WT

M14	WT	WT

MALME-3M	WT	WT

MDA-MB-435	WT	WT

SK-MEL-2	WT	WT

SK-MEL-28	WT	WT

SK-MEL-5	WT	WT

ACC-257	WT	WT

UACC-62	WT	WT

BRAF mutant

WT

V600E

V600E

WT

WT

WT

V600E

V600E

V600E

V600E

V600E

V600E

V600E

V600E

V600E


	Tolvaptan group	Conventional group	p value

Number	26	180

Age (year	75	7	0.88


Diagnosis	Diagnostic Clues

Psoriasis	Usually involves extensor, palmar, plantar, nails and extensor areas. Thick plaques sharply limited with silvery white scales. Positive family history. Arthritis present in 10% of patients. Uncommon in children.

Atopic Dermatitis	First appearance after 3 months of age, pruritus and restlessness are common. Frequently involves scalp, cheeks and extensor areas. Flexures involvement is more frequent in older ages. Family history of atopy such as eczema, allergic rhinitis and asthma. Self resolved by age 12.

Tinea Capitis	Commonly seen in children, frequently accompanied by hair loss patches with “black dots” (broken hair). Highly contagious. KOH examination of the hair shaft and fungal culture confirm the diagnosis. Household members of patient should be examined.

Rosacea	Usually targets the face. Papulopustules and telangiectasias on the malar, nose and perioral regions with slight desquamation. Recurrent edema and flushing.

Systemic Lupus Erythematous (SLE)	In acute stage, butterfly rash on face that spares the nose bridge or nasolabial folds. Photosensitivity is common. Skin lesions are generally associated with other clinical signs of SLE. Histology and serologic tests such as antinuclear autoantibodies confirm the diagnosis.

Others	Pemphigus Foliaceous	Erythema, scaling and crusting that first present on the scalp and face can expand to chest and back. Histology, direct immunofluorescence with anti-desmoglein antibodies confirm diagnosis.

Pityriasis Rosea	Abrupt onset, appearance of herald patch and resolution within weeks.

Secondary syphilis	Peripheral lymph-adenopathy, mucosal lesions and palmoplantar macula-papules. Serology tests such as VDRL/ RPR, FTA-ABS* confirm diagnosis.

Diaper Dermatitis	Occurs on convex skin surfaces in contact with diaper, such as lower abdomen, genitalia, buttocks and upper thighs. Spares skin folds. Pustules are common.

Langerhans cell histiocytosis	Multisystem disease. Brown to purplish papules prone to coalesce on the scalp, retro-auricular areas, axillae and inguinal folds. Possible lytic bone lesions, liver, spleen and lung involvement. Histology confirms diagnosis.

Diagnosis	Diagnostic Clues

Psoriasis	Usually involves extensor, palmar, plantar, nails and extensor areas. Thick plaques sharply limited with silvery white scales. Positive family history. Arthritis present in 10% of patients. Uncommon in children.

Atopic Dermatitis	First appearance after 3 months of age, pruritus and restlessness are common. Frequently involves scalp, cheeks and extensor areas. Flexures involvement is more frequent in older ages. Family history of atopy such as eczema, allergic rhinitis and asthma. Self resolved by age 12.

Tinea Capitis	Commonly seen in children, frequently accompanied by hair loss patches with “black dots” (broken hair). Highly contagious. KOH examination of the hair shaft and fungal culture confirm the diagnosis. Household members of patient should be examined.

Rosa	Usually targets the face. Papulopustules and telangiectasias on the malar, nose and perioral regions w

cea	ith slight desquamation. Recurrent edema and flushing.

Systemic Lupus Erythematous (SLE)	In acute stage, butterfly rash on face that spares the nose bridge or nasolabial folds. Photosensitivity is common. Skin lesions are generally associated with other clinical signs of SLE. Histology and serologic tests such as antinuclear autoantibodies confirm the diagnosis.

Others	Pemphigus Foliaceous	Erythema, scaling and crusting that first present on the scalp and face can expand to chest and back. Histology, direct immunofluorescence with anti-desmoglein antibodies confirm diagnosis.

Pityriasis Rosea	Abrupt onset, appearance of herald patch and resolution within weeks.

Secondary syphilis	Peripheral lymph-adenopathy, mucosal lesions and palmoplantar macula-papules. Serology tests such as VDRL/ RPR, FTA-ABS* confirm diagnosis.

Diaper Dermatitis	Occurs on convex skin surfaces in contact with diaper, such as lower abdomen, genitalia, buttocks and upper thighs. Spares skin folds. Pustules are common.

Langerhans cell histiocytosis	Multisystem disease. Brown to purplish papules prone to coalesce on the scalp, retro-auricular areas, axillae and inguinal folds. Possible lytic bone lesions, liver, spleen and lung involvement. Histology confirms diagnosis.


Assembler	Type†	Splits reads*	Author	Cost	Source available	URL

CAP3	OLC†	No	X Huang and A Madan [38]	Free for use at non-profit organizations	No	http://seq.cs.iastate.edu/

CLC Assembly Cell 3.0	de Bruijn graph	Yes	CLC	Request quote or trial license	No	http://www.clcbio.com/

MIRA 3.0	OLC	No	Bastien Chevreux [40]	Free	Yes, GPL	http://sourceforge.net/projects/mira-assembler/

Newbler 2.3 and Newbler 2.5	OLC	Yes	Roche 454 [37]	Free for academic use	No	http://454.com/products-solutions/analysis-tools/gs-de-novo-assembler.asp

SeqMan NGen 2.1	OLC	No	DNAStar [41]	Request quote or trial license	No	http://www.dnastar.com/t-products-seqman-ngen.aspx


		MZ	DZ	Total no pairs

IBS	Concordant pairs	14	10	24

Discordant pairs	95	193	288

Probandwise concordance rate	0.23	0.09*

Depression	Concordant pairs	67	82	149

Discordant pairs	232	455	687

Probandwise concordance rate	0.22	0.15*

Anxiety	Concordant pairs	56	55	111

Discordant pairs	186	422	608

Probandwise concordance rate	0.23	0.12*

Depression	Probandwise concordance rate	0.22	0.15*

Anxiety	Concordant pairs	56	55	111

Discordant pairs	186	422	608

Probandwise concordance rate	0.23	0.12*


 	Ashford et al.[46](MMSE)	Gibbons et al.[48]UK (MMSE)	Gibbons et al.[48]US (MMSE)	Mungas and Reed[1](BIMCT/MMSE)

Truncated above upper limit	Recall: tree	No ifs ands or buts

Recall: flag	Recall nouns

1st quartile (most difficult)	Serial sevens: subtraction 5	Orientation to date	Orientation to date	Recall ‘42’ (BIMCT)

Serial sevens: subtraction 3	Verbal directions	No ifs ands or buts	Recall ‘Market Street’ (BIMCT)

Orientation to date	Intersecting pentagons	Intersecting pentagons	Recall ‘John’ (BIMCT)

Recall: Ball	Serial sevens	Serial sevens	Recall ‘Chicago’ (BIMCT)

Recall ‘Brown’ (BIMCT)

2nd quartile	Serial sevens: subtraction 4	Orientation to year	Recall nouns	Orientation to year (BIMCT/MMSE)

Serial sevens: subtraction 2	Orientation to county/streets	Orientation to day	Orientation to month (BIMCT/MMSE)

Orientation to day	Orientation to day	Orientation to year	Age (BIMCT)

Orientation to county	Orientation to month	Orientation to season

Orientation to month	 	Orientation to month

Serial sevens: subtraction 1	 	Orientation to county/streets

Orientation to year

Orientation to season

Orientation to place

Orientation to floor

3rd quartile	Orientation to city	Orientation to state/county	Orientation to address	Orientation to state (MMSE)

Intersecting pentagons	Write sentence	Verbal directions	Type of work (BIMCT)

Orientation to state	Orientation to	Write sentence	Count forward (BIMCT)

Write sentence	Season	Orientation to place	Name watch (MMSE)

No ifs ands or buts	Orientation to Address	Orientation to city

Name watch

Verbal directions: paper-on floor

4th quartile (least difficult)	Close eyes	Repeat nouns	Orientation to state	Place of birth (BIMCT)

Repeat: flag	Orientation to city/town/village	Close eyes	Name pencil (MMSE)

Name pencil	Orientation to room	Name objects	Name (BIMCT)

Repeat: ball

Repeat: tree

Verbal directions: paper-take in right hand

Verbal directions: paper-fold in half

Truncated below 0	 	Close eyes	Repeat nouns

Name objects


Definition	Grade	Ki-67%	Mitotic index

NET - neuroendocrine tumour, low grade	G1	≤2	<2

NET - neuroendocrine tumour, intermediate grade	G2	3 to 20	2 to 20

NET - neuroendocrine carcinoma, high grade	G3	>20	>20


	Ectopic pregnancya	Preterm delivery among live-born infantsb

	n (prevalence %)	Adjusted odds ratio (95% confidence interval)	n (prevalence %)	Adjusted odds ratio (95% confidence interval)

Mother not diagnosed with SLE	5 (0.7%)	1.0 (-)	26 (4.7%)	1.0 (-)

Mother diagnosed with SLE	5 (1.4%)	3.6 (0.7–18.7)	19 (7.3%)	1.5 (0.7–3.2)

Pregnancy conceived prior to SLE diagnosis	3 (0.8%)	3.1(0.5–17.9)	12 (4.7%)	1.2(0.5–2.8)

Pregnancy conceived after SLE diagnosis	2 (0.6%)	7.5 (0.9–62.5)	7 (2.7%)	3.4 (1.2–10.0)

	Ectopic pregnancya	Preterm delivery among live-born infantsb

	n (prevalence %)	Adjusted odds ratio (95% confidence interval)	n (prevalence %)	Adjusted odds ratio (95% confidence interval)

Pregnancy conceived prior to SLE diagnosis	3 (0.8%)	3.1(0.5–17.9)	12 (4.7%)	1.2(0.5–2.8)

Pregnancy conceived after SLE diagnosis	2 (0.6%)	7.5 (0.9–62.5)	7 (2.7%)	3.4 (1.2–10.0)


Block 1 set	Block 2 set	Block 3set	Block 4 set	Block 5 set	Block 6 set	Block 7 set	Block 8 set

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	OG1	NT	NT	OG2	NT	NT

NT	NT	OG1	NT	NT	OG2	NT	NT

NT	OG2	OG1	NT	NT	OG2	OG1	NT

NT	OG2	NT	T(probe)	T(probe)	NT	OG1	NT

NT	OG2	T(probe)	NT	NT	T(probe)	OG1	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	NT	NT	NT	NT	NT(probe)	NT

NT	NT	NT	NT	NT	NT	NT	NT

PG1	NT	NT	NT	NT	NT	NT	PG2

PG1	T	NT	NT	NT	NT	T	PG2

PG1	NT	NT	NT	NT	NT	NT	PG2

NT	NT	NT	NT	NT	NT	NT	NT

T(probe)	NT	T	NT	NT	T	NT	T(probe)

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T	NT	NT	NT	NT	T	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	T(probe)	T(probe)	NT	NT	NT

T	NT	PG1	NT	NT	PG2	NT	T

NT	NT	PG1	NT	NT	PG2	NT	NT

NT	NT	PG1	NT	NT	PG2	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	T(probe)	NT	NT	T(probe)	NT	NT

T(probe)	PG2	NT	OG2	OG1	NT	PG1	T(probe)

NT	PG2	NT	OG2	OG1	NT	PG1	NT

NT	PG2	NT	OG2	OG1	NT	PG1	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	NT	T(probe)	T(probe)	NT	T(probe)	NT

OG1	NT	NT	NT	NT	NT	NT	OG2

OG1	NT	NT	NT	NT	NT	NT	OG2

OG1	NT	T	T	T	T	NT	OG2

NT	NT	NT	NT	NT	NT	NT	NT

T(probe)	NT	NT	NT	NT	NT	NT	T(probe)

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	T(probe)	NT	NT	T(probe)	T(probe)	NT

NT	NT	NT	T	T	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

T	NT	NT	NT	NT	NT	NT	T

NT	NT	NT	NT	NT	NT	NT	NT

Block 1 set	Block 2 set	Block 3set	Block 4 set	Block 5 set	Block 6 set	Block 7 set	Block 8 set

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	OG1	NT	NT	OG2	NT	NT

NT	NT	OG1	NT	NT	OG2	NT	NT

NT	OG2	OG1	NT	NT	OG2	OG1	NT

NT	OG2	NT	T(probe)	T(probe)	NT	OG1	NT

NT	OG2	T(probe)	NT	NT	T(probe)	OG1	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	NT	NT	NT	NT	NT(probe)	NT

NT	NT	NT	NT	NT	NT	NT	NT

PG1	NT	NT	NT	NT	NT	NT	PG2

PG1	T	NT	NT	NT	NT	T	PG2

PG1	NT	NT	NT	NT	NT	NT	PG2

NT	NT	NT	NT	NT	NT	NT	NT

T(probe)	NT	T	NT	NT	T	NT	T(probe)

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T	NT	NT	NT	NT	T	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	PG2	PG1	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	NT	T(probe)	T(probe)	NT	NT	NT

T	NT	PG1	NT	NT	PG2	NT	T

NT	NT	PG1	NT	NT	PG2	NT	NT

NT	NT	PG1	NT	NT	PG2	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	NT	T(probe)	NT	NT	T(probe)	NT	NT

T(probe)	PG2	NT	OG2	OG1	NT	PG1	T(probe)

NT	PG2	NT	OG2	OG1	NT	PG1	NT

NT	PG2	NT	OG2	OG1	NT	PG1	NT

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	NT	T(probe)	T(probe)	NT	T(probe)	NT

OG1	N	N	NT		NT	N

	T	T		NT		T	OG2

OG1	NT	NT	NT	NT	NT	NT	OG2

OG1	NT	T	T	T	T	NT	OG2

NT	NT	NT	NT	NT	NT	NT	NT

T(probe)	NT	NT	NT	NT	NT	NT	T(probe)

NT	NT	NT	NT	NT	NT	NT	NT

NT	T(probe)	T(probe)	NT	NT	T(probe)	T(probe)	NT

NT	NT	NT	T	T	NT	NT	NT

NT	NT	NT	NT	NT	NT	NT	NT

T	NT	NT	NT	NT	NT	NT	T

NT	NT	NT	NT	NT	NT	NT	NT


Institutions	Key informant interview	Group Interview	Focus Group Discussion

National Level

MoH	10	0	0

PMU and CCM	6	0	1

WHO	3	0	0

SRs	10	0	0

TAIS	1	0	0

CARE International	1	0	0

Districts and CHCs	8	5	6

Health cadres and teachers	5	1	0

Local Authority	5	0	0

Community members	0	0	9

SR field officers	6	2	0

Donors	3

Total	58	8	16

Institutions	Key informant interview	Group Interview	Focus Group Discussion

National Level

MoH	10	0	0

PMU and CCM	6	0	1

WHO	3	0	0

SRs	10	0	0

T		0

Institutions	Key informant interview	Group Interview	Focus Group Discussion

AIS	1		0

CARE International	1	0	0

Districts and CHCs	8	5	6

Health cadres and teachers	5	1	0

Local Authority	5	0	0

Community members	0	0	9

SR field officers	6	2	0

Donors	3

Total	58	8	16


		Age at infection	Serotypea	Serologic responseb	Clinical categoryc

	Infection order	1	2	3	1	2	3	1	2	3	1	2	3

Indiv.	Titers > 10d

1	0	8.7	12.8	14.9	ND	NEG	DEN4	ND	S	S	SubC/nhDF	DHF	DHF

2	0	8.9	10.9	12.2	ND	ND	ND	ND	ND	ND	SubC	SubC	SubC

3	ND	10.5	10.8	10.9	NEG	DEN1	NEG	S	S	S	nhDF/hDF	hDF	hDF

4	0	7.7	8.7	11.0	ND	ND	DEN2	ND	ND	S	SubC/nhDF	SubC/nhDF	nhDF

5	4	7.5	8.5	10.5	ND	ND	ND	ND	ND	ND	SubC	SubC	SubC

6	0	7.9	9.2	12.2	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC	SubC

7	0	7.9	9.4	12.8	DEN1	NEG	ND	S	S	ND	DHF	nhDF	SubC

8	4	9.0	12.3	12.9	ND	ND	DEN2	ND	ND	S	SubC	SubC	DHF

9	ND	5.9	9.3	10.2	NEG	ND	ND	S	ND	ND	DHF	SubC	SubC

10	4	7.8	9.0	10.3	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC	SubC

11	ND	9.1	11.1	11.8	DEN1	DEN3	ND	S	S	ND	hDF	nhDF	SubC/nhDF

12	0	7.8	10.8	12.3	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC/nhDF	SubC

13	0	7.8	8.8	10.1	ND	ND	DEN2	ND	ND	S	SubC/nhDF	SubC/nhDF	nhDF

14	ND	5.3	8.7	9.8	NEG	DEN2	ND	S	S	ND	DHF	nhDF	SubC

Age at infection	Serotypea	Serologic responseb	Clinical categoryc

3	1	2	3	1	2	3	1	2	3

14.9	ND	NEG	DEN4	ND	S	S	SubC/nhDF	DHF	DHF

12.2	ND	ND	ND	ND	ND	ND	SubC	SubC	SubC

10.9	NEG	DEN1	NEG	S	S	S	nhDF/hDF	hDF	hDF

11.0	ND	ND	DEN2	ND	ND	S	SubC/nhDF	SubC/nhDF	nhDF

10.5	ND	ND	ND	ND	ND	ND	SubC	SubC	SubC

12.2	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC	SubC

12.8	DEN1	NEG	ND	S	S	ND	DHF	nhDF	SubC

12.9	ND	ND	DEN2	ND	ND	S	SubC	SubC	DHF

10.2	NEG	ND	ND	S	ND	ND	DHF	SubC	SubC

10.3	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC	SubC

11.8	DEN1	DEN3	ND	S	S	ND	hDF	nhDF	SubC/nhDF

12.3	ND	ND	ND	ND	ND	ND	SubC/nhDF	SubC/nhDF	SubC

10.1	ND	ND	DEN2	ND	ND	S	SubC/nhDF	SubC/nhDF	nhDF

9.8	NEG	DEN2	ND	S	S	ND	DHF	nhDF	SubC


Targeted Viruses	Name	Sequence of Oligonucleotide (5'–3')	Location	Amplicon Length

Hepatitis A Virus	Forward primer	GGT AGG CTA CGG GTG AAA C	393~411 a	116 nt

Reverse primer	CCT CCG GCG TTG AAT GGT TT	489~508 a

Probe	FAM-ACA GCG GCG GAT ATT GGT GAG TTG TTA AGA-BHQ	456~485 a

Hepatitis E Virus	Forward primer	GGT GGT TTC TGG GGT GAC	5261~5278 b	70 nt

Reverse primer	AGG GGT TGG TTG GAT GAA	5313~5330 b

Probe	Cy5-TGA TTC TCA GCC CTT CGC-BHQ	5284~5301 b

Hepatitis E Virus	Probe	Cy5-TGA TTC TCA GCC CTT CGC-BHQ	5284~5301 b	70 nt


Variables	Group I (%)	Group II (%)	p-value

Mean cardiopulmonary bypass time (minutes)	104 ± 41	98 ± 53	0.34

Mean aortic cross-clamping time (minutes)	82 ± 32	78 ± 37	0.41

Annulus enlargement	36 (13.6 %)	4 (6.9 %)	0.24

Mitral valve replacement	31 (11.7 %)	4 (6.9 %)	0.41

Coronary artery bypass grafting	37 (14 %)	7 (12 %)	0.87

 Total grafts	66 (25 %)	12 (20.7 %)

Associated carotid endarterectomy	4 (1.5 %)	0	0.78

Tricuspid valve repair	8 (3 %)	4 (6.9 %)	0.30

Postoperative outcome

Mean mechanical ventilation (hours)	9.8 ± 9.5	12.3 ± 14	0.10

Mean Intensive Care Unit stay (days)	3 ± 6.4	2.7 ± 2.6	0.73

Readmitted in Intensive Care Unit	8 (3 %)	3 (5.2 %)	0.68

Postoperative complications	52 (19.6 %)	14 (24 %)	0.55

Low cardiac output	39 (14.7 %)	9 (15.5 %)	0.96

Myocardial infarction	10 (3.8 %)	2 (3.5 %)	0.79

Ventricular arrhythmias	27 (10 %)	5 (8.6 %)	0.91

Heart Block	4 (1.5 %)	1 (1.7 %)	0.64

Reoperation for bleeding	15 (5.7 %)	3 (5.2 %)	0.87

Blood used	126 (47.6 %)	30 (52 %)	0.67

Pulmonary complications	17 (6.4 %)	5(8.6 %)	0.75

 ARDS	3 (1.1 %)	1 (1.7 %)	0.78

 Pneumonia	9 (3.4 %)	2 (3.5 %)	0.71

Reintubation	12 (4.5 %)	3 (5.2 %)	0.90

Neurological complications	9 (3.4 %)	0.33

Stroke	2 (0.75 %)	0	0.80

Infectious complications	14 (5.3 %)	4 (6.9 %)	0.87

 Septicemia	5 (2 %)	1 (1.7 %)	0.65

 Deep sternal wound infection	4 (1.5 %)	2 (3.5 %)	0.64

 Superficial sternal wound infection	5 (2 %)	1 (1.7 %)	0.65

Renal complications	19 (7.2 %)	9 (15.5 %)	0.08

Hemodialysis	7 (2.6 %)	3 (5.2 %)	0.56

Multi organ failure	5 (2 %)	1 (1.7 %)	0.65

Coagulopathy	5 (2 %)	1 (1.7 %)	0.65

Hospital death	14 (5.3 %)	4 (6.9 %)	0.87

 Hospital death in reoperated patients	6 (2.3 %)	2 (3.5 %)	0.22

Causes of hospital death

 Cardiac	8 (3 %)	3 (5.2 %)	1.0

 Septicemia	1 (0.4 %)	0	1.0

 Intestinal infarction	1 (0.4 %)	0	1.0

 Multi organ failure	3 (1.1 %)	1 (1.7 %)	1.0

 Aortic dissection	1(0.4 %)	0	1.0

Variables	Group I (%)	Group II (%)	p-value

Intestinal infarction	1 (0.4 %)	0	1.0

Multi organ failure	3 (1.1 %)	1 (1.7 %)	1.0

Aortic dissection	1(0.4 %)	0	1.0


SDQ Variables	CBCL Variables	rs	p-value

Emotional symptoms	Anxiety/depression	0.480	0.002

Total internalizing problems	0.503	0.001

Attention/hyperactivity	0.412	0.008

Stress problem	0.546	<0.001

Total of EB problems	0.437	0.005

Anxiety/depression	0.437	0.005

Conduct problems	Total internalizing problems	0.501	0.001

Aggressive behavior	0.600	<0.001

Attention/hyperactivity	0.489	0.001

Total externalizing problems	0.675	<0.001

Stress problem	0.637	<0.001

Total of EB problems	0.664	<0.001

Hyperactivity problem	Attention/hyperactivity	0.586	<0.001

Stress problem	0.466	0.002

Total of probelms	0.401	0.010

Peer relationship problem	Anxiety/depression	0.468	0.002

Emotionally reactive 	0.422	0.007

Total internalizing problems	0.474	0.002

Total of EB problems	0.440	0.004

Prosocial behavior	Aggressive behavior	-0.340	0.030

Withdrawal	-0.330	0.036

Total of difficulty	Attention/hyperactivity	0.606	<0.001

Aggressive behavior	0.486	0.001

Total externalizing problems	0.595	<0.001

Anxiety/depression	0.579	0.001

Emotionally reactive 	0.486	0.002

Total internalizing problems	0.596	<0.001

Stress problem	0.669	<0.001

Total of EB problems	0.641	0.001

Impact of the difficulty	Aggressive behavior	0.540	<0.001

Total externalizing EB problems	0.522	<0.001

Total of problems	0.467	0.003

SDQ Variables	CBCL Variables	rs	p-value

Emotional symptoms	Anxiety/depression	0.480	0.002

Total internalizing problems	0.503	0.001

Attention/hyperactivity	0.412	0.008

Stress problem	0.546	<0.001

Total of EB problems	0.437	0.005

Anxiety/depression	0.437	0.005

Co	Total internalizing problems	0.501	0.001

Aggressive behavior	0.600	<0.001

Attention/hyperactivity	0.489	0.001

Total externa	0.	<

nduct problems	lizing problems	675	0.001

Stress problem	0.637	<0.001

Total of EB problems	0.664	<0.001

Hyperactivity problem	Attention/hyperactivity	0.586	<0.001

Stress problem	0.466	0.002

Total of probelms	0.401	0.010

Peer relationship problem	Anxiety/depression	0.468	0.002

Emotionally reactive	0.422	0.007

Total internalizing problems	0.474	0.002

Total of EB problems	0.440	0.004

Prosocial behavior	Aggressive behavior	-0.340	0.030

Withdrawal	-0.330	0.036

Total of difficulty	Attention/hyperactivity	0.606	<0.001

Aggressive behavior	0.486	0.001

Total externalizing problems	0.595	<0.001

Anxiety/depression	0.579	0.001

Emotionally reactive	0.486	0.002

Total internalizing problems	0.596	<0.001

Stress problem	0.669	<0.001

Total of EB problems	0.641	0.001

Impact of the difficulty	Aggressive behavior	0.540	<0.001

Total externalizing EB problems	0.522	<0.001

Total of problems	0.467	0.003


Domains	Amino acid Positions

PWWP1	323–388


 	Intervention departments	Control departments	Significance tests

 	Baseline	Follow-up	Baseline	Follow-up	Group x Time

 	N = 410	N = 604	N = 286	N = 281	(ANOVA)

Indicators of patient care quality	M	SD	M	SD	M	SD	M	SD	F(df = 1); p

1 Organization of physicians’ care	4.20	.82	4.23	.75	4.13	.76	4.01	.84	3.67; .056†

2 Quality of information from physicians	4.08	.83	4.16	.77	3.88	.88	3.93	.81	0.14; n. s.


AEROBIC

Frequency:	20-60 min/day - 3-5 days/week

Intensity:	Light (< 40% HRR or VO2R); Moderate (40-60% HRR or VO2R); Hard (> 60% HRR or VO2R)

Type:	Walk or Cicle

RESISTANCE

Frequency:	2-3x/week

Intensity:	Light (40-50% 1MR); Moderate (60-80% 1MR); Hard (>80% 1MR)

Type:	Progressive (2-4 sets; 8-15 reps; Large Muscle Groups)

FLEXIBILITY

Frequency:	2-3x/week

Intensity:	10-30 sec (to the point of discomfort)

Type:	Static Stretching, Dynamic, and PNF, with Emphasis on Spine and Trunk

BALANCE

Frequency:	10-15 min - 2-3x/week

Intensity:	There is no Evidence of the Intensity

Type:	Exercises Involving Motor Skills (Balance, Agility, Coordination, Gait, and Proprioception)

AEROBIC

RESISTANCE

Frequency:	2-3x/week

Intensity:	Light (40-50% 1MR); Moderate (60-80% 1MR); Hard (>80% 1MR)

Type:	Progressive (2-4 sets; 8-15 reps; Large Muscle Groups)

FLEXIBILITY

Frequency:	2-3x/week

Intensity:	10-30 sec (to the point of discomfort)

Type:	Static Stretching, Dynamic, and PNF, with Emphasis on Spine and Trunk

BALANCE

Frequency:	10-15 min - 2-3x/week

Intensity:	There is no Evidence of the Intensity

Type:	Exercises Involving Motor Skills (Balance, Agility, Coordination, Gait, and Proprioception)


Groups

Group A

Group B

Group C

Group D†

Group E


	Transplanted organ (n)	EAS characteristics and outcomes

Authors, Year	Liver	Heart	Lung	Kidney	Patients undergoing EAS (n)	EAS Rate (%)	Surgical procedures (n)	Morbidity [n (%)]	Mortality [n (%)]

Cruz RJ Jr et al., 2012 [26]	5677				7	0,12	BR (7)	n/a	2 (28.6)

Lahon B et al., 2011 [13]			351		3	0.85	BR (3)	n/a	0 (0)

Paul S et al., 2009 [4]			208		14	6.73	LA (14)	n/a	1 (7.1)

Miller CB et al., 2006 [41]			229		2	0.87	BR (1), LA (1)	n/a	1 (50)

Karakayali H et al., 2002 [32]				1038	1	0.10	BR (1)	n/a	0 (0)

Andreoni KA et al., 1999 [33]				1417	4	0.28	BR (4)	n/a	1 (25)

Bhatia DS et al., 1997 [21]		349			5	1.43	BR (5)	1 (20)	0

Total	5677	349	788	2455	36	0.39	BR (21), LA (15)	n/a	5 (13.9)

	Transplanted organ (n)	EAS characteristics and outcomes

Authors, Year	Liver	Heart	Lung	Kidney	Patients undergoing EAS (n)	EAS Rate (%)	Surgical procedures (n)	Morbidity [n (%)]	Mortality [n (%)]

Cruz RJ Jr et al., 2012 [26]	5677				7	0,12	BR (7)	n/a	2 (28.6)

Lahon B et al., 2011 [13]			351		3	0.85	BR (3)	n/a	0 (0)

Paul S 			20					n

	Transplanted organ (n)	EAS characteristics and outcomes

Authors, Year	Liver	Heart	Lung	Kidney	Patients undergoing EAS (n)	EAS Rate (%)	Surgical procedures (n)	Morbidity [n (%)]	Mortality [n (%)]

et al., 2009 [4]			8		14	6.73	LA (14)	/a	1 (7.1)

Miller CB et al., 2006 [41]			229		2	0.87	BR (1), LA (1)	n/a	1 (50)

Karakayali H et al., 2002 [32]				1038	1	0.10	BR (1)	n/a	0 (0)

Andreoni KA et al., 1999 [33]				1417	4	0.28	BR (4)	n/a	1 (25)

Bhatia DS et al., 1997 [21]		349			5	1.43	BR (5)	1 (20)	0

Total	5677	349	788	2455	36	0.39	BR (21), LA (15)	n/a	5 (13.9)


	Women		Test for group difference	Sign.	Effect size	Men		Test for group difference	Sign.	Effect size

Subscale	n	M(SD)	t	p	d	n	M(SD)	t	p	d

Sexual desire/frequency			21.28	<0.001	1.403			8.73	<0.001	1.388

Before cancer	520	6.85 (1.64)				117	7.40 (1.33)

After cancer	520	4.92 (1.86)				117	5.86 (1.97)

Sexual desire/interest			16.63	<0.001	1.228			6.75	<0.001	1.285

Before cancer	516	8.82 (2.51)				115	10.74 (2.12)

After cancer	516	6.77 (2.62)				115	9.17 (2.44)


ABC subfamily	Bombyx mori	Drosophila melanogaster	Anopheles gambiae	Tribilium castaneum	Apis mellifera	Homo sapiens

A	6	10	9	9	3	13

B	8	8	5	6	7	11

C	15	14	13	31	9	12

D	2	2	2	2	2	4

E	1	1	1	1	1	1

F	3	3	3	3	3	3

G	13	15	16	13	15	5

H	3	3	3	3	3	0

Total	51	56	52	68	43	48

ABC subfamily	Bombyx mori	Drosophila melanogaster	Anopheles gambiae	Tribilium castaneum	Apis mellifera	Homo sapiens

		2	2		2	4

E	1	1	1	1	1	1

F	3	3	3	3	3	3

G	13	15	16	13	15	5

H	3	3	3	3	3	0

Total	51	56	52	68	43	48


	Intervention villages	Control village

	 Village 12	Village13	Village 14	Village15	Total	Chikore

S. haematobium

 Number positive	5	5	4	8	22	10

 Number negative	98	58	42	57	255	69

 Prevalence	4.9%	7.9%	8.7%	12.3	7.9%	12.7%

S. mansoni

 Number positive	0	3	3	3	9	No data

 Number negative	103	60	43	62	268	No data

 Prevalence	0	4.8	6.5	4.6	3.4%	No data


Strategy	Cost	Incremental cost	Live births	Cost per live birth	ICER vs. eS ET	ICER vs Embry Dx SET

eSET	€14,896	-	0.314	 €47,439

Embryo-Dx SET	€16,687	€1,791	0.43	 €38,807	€15,439

DET	€18,952	€2,265	0.473	 €40,068	€25,509	€52,674

		€4,056‡


Characteristics	n (%)

Maternal age (years)

<20	40 (9.1)

20–24	163 (36.9)

25–29	144 (32.6)

30–34	66 (14.9)

≥35	29 (6.6)

Parity

0	139 (31.5)

≥1	303 (68.6)

Race/ethnicity

Latina	426 (96.4)

Non-Latina, white	7 (1.6)

Other	9 (2.0)

Marital status

Married or living as married	356 (80.5)

Unmarried	86 (19.5)

Maternal education

≤6th grade	188 (42.5)

Some high school	158 (35.8)

High school graduate	96 (21.7)

Family income

≤ Poverty	272 (61.5)

Poverty–200%	154 (34.8)

>200%	16 (3.6)

Country of birth

United States	59 (13.4)

Mexico	374 (84.6)

Other	9 (2.0)

Years of residence in the United States

≤5 years	230 (52.0)

6–10 years	99 (22.4)

≥11 years	63 (14.3)

Entire life	50 (11.3)

Work status during pregnancy

Did not work	172 (38.9)

Some field or agricultural work	181 (41.0)

Other work	89 (20.1)

Prepregnancy body mass index (kg/m2)

Underweight (<18.5)	2 (0.5)

Normal (18.5–24.9)	170 (38.5)

Overweight (25–29.9)	175 (39.6)

Obese (>30)	95 (21.5)

Smoked during pregnancy

Yes	26 (5.9)

No	416 (94.1)

Any moves during pregnancy

Yes	182 (41.2)

No	260 (58.8)

Low birth weighta infant

Yes	17 (3.9)

No	425 (96.2)

Pretermb infant

Yes	30 (6.8)

No	412 (93.2)

aLow birth weight is defined as <2,500g.bPreterm birth is defined as <37 weeks gestation.


Intake scenarios	Exposure for different ethyl carbamate concentration scenarios in spirits [ng/kg bw/day]

Drinks per day	Volume of spirit consumed [mL]	Mean	Median	90th percentile	95th percentile	99th percentile

1	25	21	17	42	58	92

2	50	42	33	83	117	183

3	75	63	50	125	175	275

4	100	83	67	167	233	367

5	125	104	83	208	292	458

Intake scenarios	Exposure for different ethyl carbamate concentration scenarios in spirits [ng/kg bw/day]

Drinks per day	Volume of spirit consumed [mL]	Mean	Median	90th percentile	95th percentile	99th percentile

1	25	21	17	42	58	92

2	50	42	33	83	117	183

3	75	63	50	125	175	275

	10	83	6	167	23	367


	ELISA titer anti-STn

IgG

KLH	< 100

1-KLH	15309

2-KLH	293812

3-KLH	7384

4-KLH	555186


Complication	Total vivax	Total patients with severity sign	Pooled prevalence, %	95% CI, %

Death	46411	353	0.3	0.1–0.4

Cerebral malaria	45845	532	0.8	0.5–1.1

Multiple convulsions	46386	88	0.2	0–0.5

Renal dysfunction	46341	244	1.1	0.3–1.9

Respiratory dysfunction	46411	144	0.3	0.1–0.5

Hepatic dysfunction	46536	727	4.2	3.2–5.2

Abnormal bleeding/DIC	46346	206	0.6	0.2–1

Haemoglobinuria	46411	93	0.1	0–0.4

Hypoglycaemia	46381	44	1.8	0.9–2.7

Metabolic acidosis	46341	138	1	0–2.3

Circulatory collapse/Shock	46411	67	5.1	2.5–7.7

Severe anaemia	46411	2276	4	2.9–5.1

Severe thrombocytopenia	45775	888	8.6	5.4–11.8